HUE031755T2 - Pirazol vegyületek sigma receptor inhibitorokként - Google Patents

Description

# European II 11 II II II I II I INI 11 Mil I II I II

Patent Office =Pien ου EP 2 576 543 B1

(12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 231112 <2006 01> C07D 231114 <2006 01> 21.12.2016 Bulletin 2016/51 C07D 401I04<2006 01> C07D 413I12<2006 01> (21) Application number: 11723422.9 (86) International application number: PCT/EP2011/058633 (22) Date of filing: 26.05.2011 (87) International publication number: WO 2011/147910 (01.12.2011 Gazette 2011/48)

(54) PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS

PYRAZOLVERBINDUNGEN ALS SIGMA-REZEPTORHEMMER COMPOSÉS PYRAZOLE COMME INHIBITEURS DU RÉCEPTEUR SIGMA (84) Designated Contracting States: · DATABASE WPI Week 200451 Thomson AL AT BE BG CH CY CZ DE DK EE ES Fl FR GB Scientific, London, GB; AN 2004-529624

GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO XP002605609, -&amp; JP 2004 196678 A (DAINIPPON PL PT RO RS SE Sl SK SM TR PHARM CO LTD) 15 July 2004 (2004-07-15)

Designated Extension States: · PETRIE C R ET AL: "A NOVEL BIOTINYLATED

BA ME ADENYLATE ANALOGUE DERIVED FROM

PYRAZOLOÚ3.4-D 3/4 PYRIMIDINE FOR

(30) Priority: 27.05.2010 EP 10382148 LABELING DNA PROBES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US LNKD- (43) Date of publication of application: D0l:10.1021/BC00012A011, vol. 2, no. 6, 1 10.04.2013 Bulletin 2013/15 November 1991 (1991-11-01), pages 441-446, XP000572789, ISSN: 1043-1802 (73) Proprietor: Laboratorios del Dr. Esteve, S.A. · D.-M. SHEN, M. SHU, K. T. CHAPMAN: "Versatile 08041 Barcelona (ES) and Efficient Solid-Phase Syntheses of Pyrazoles and Isoxazoles", ORGANIC LETTERS, vol. 2, no. (72) Inventors: 18, 8 April 2000 (2000-04-08), pages 2789-2792, • GARCIA LÓPEZ, Monica XP002605610, E-08018 Barcelona (ES) · K. V. SHVIDENKO, K. G. NAZARENKO, T. I. • TORRENS JOVER, Antoni SHVIDENKO, A. A. TOLMACHEV: "Recyclization E-08221 Terrasa - Barcelona (ES) Reactions of • DÍAZ FERNANDEZ, José Luis 2-(1-Benzoylpyrrolidin-2-ylidene)malononitrile", E-08240 Manresa - Barcelona (ES) CHEMISTRY OF HETEROCYCLIC COMPOUNDS, • CAAMANO MOURE, Ana Maria vol. 46, no. 1, 1 May 2010 (2010-05-01), pages E-15705 Santiago de Compostela - A Coruna (ES) 56-60, XP002605611,

• DATABASE BEILSTEIN [Online] BEILSTEIN (74) Representative: ABG Patentes, S.L. INSTITUTE FOR ORGANIC CHEMISTRY,

Avenida de Burgos, 16D FRANKFURT-MAIN, DE;

Edificio Euromor "Diethyl-[3-(5-methyl-1-phenyl-1H-pyrazol- 28036 Madrid (ES) 3-yl)-propyl]amine", XP002605612, Database accession no. 213356 &amp; M. J. S. DEWAR: (56) References cited: "Attempts to find new Antimalarials. Part XXI", ) EP-A1- 1 829 866 EP-A2-0 248 594 JOURNAL OF THE CHEMICAL SOCIETY, 1944, > WO-A1-2007/002559 WO-A2-2008/108517 pages 615-619, F US-B1- 6 509 367 )__ J Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent I Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the

Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been ! paid. (Art. 99(1) European Patent Convention). • DATABASE BEILSTEIN [Online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; "Methyl-{3-[5-(4-nitro-phenyl)-1-phenyl-1 H -pyrazol-3-yl]propyl}-amine", XP002605613, Database accession no. 705147 &amp; V. VIRMANI ET AL.: INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 17, 1979, pages 472-477, • DATABASE BEILSTEIN [Online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; "Methyl-{5-[5-(4-nitro-phenyl)-1-phenyl-1 H -pyrazol-3-yl]-pentyl}-amine", XP002605615, Database accession no. 710983 &amp; V. VIRMANI ET AL.: INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 17, 1979, pages 472-477, Remarks: The file contains technical information submitted after the application was filed and not included in this specification • DATABASE BEILSTEIN [Online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; "Methyl-{4-[5-(4-nitro-phenyl)-1-phenyl-1 H -pyrazol-3-yl]-butyl}amine", XP002605614, Database accession no. 706821 &amp; V. VIRMANI ET AL.: INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 17, 1979, pages 472-477,

Description

FIELD OF THE INVENTION

[0001] The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to some pyrazole derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment or prophylaxis of a sigma receptor mediated disease or condition.

BACKGROUND

[0002] The search for new therapeutic agents has been greatly aided in recent years by better understanding of the structure of proteins and other biomolecules associated with target diseases. One important class of these proteins is the sigma (σ) receptor, a cell surface receptor of the central nervous system (CNS) which may be related to the dysphoric, hallucinogenic and cardiac stimulant effects of opioids. From studies of the biology and function of sigma receptors, evidence has been presented that sigma receptor ligands may be useful in the treatment of psychosis and movement disorders such as dystonia and tardive dyskinesia, and motor disturbances associated with Huntington’s chorea or Tourette’s syndrome and in Parkinson’s disease (Walker, J.M. et al, Pharmacological Reviews, 1990, 42, 355). It has been reported that the known sigma receptor ligand rimcazole clinically shows effects in the treatment of psychosis (Snyder, S.H., Largent, B.L. J. Neuropsychiatry 1989, 1, 7). The sigma binding sites have preferential affinity for the dextrorotatory isomers of certain opiate benzomorphans, such as (+)SKF 10047, (+)cyclazocine, and (+)pentazocine and also for some narcoleptics such as haloperidol.

[0003] The sigma receptor has at least two subtypes, which may be discriminated by stereoselective isomers of these pharmacoactive drugs. SKF 10047 has nanomolar affinity for the sigma 1 (σ-1 ) site, and has micromolar affinity for the sigma (σ-2) site. Haloperidol has similar affinities for both subtypes. Endogenous sigma ligands are not known, although progesterone has been suggested to be one of them. Possible sigma-site-mediated drug effects include modulation of glutamate receptor function, neurotransmitter response, neuroprotection, behavior, and cognition (Quirion, R. et al. Trends Pharmacol. Sei., 1992, 13:85-86). Most studies have implied that sigma binding sites (receptors) are plasmale-mmal elements of the signal transduction cascade. Drugs reported to be selective sigma ligands have been evaluated as antipsychotics (Hanner, M. et al. Proc. Natl. Acad. Sei., 1996, 93:8072-8077). The existence of sigma receptors in the CNS, immune and endocrine systems have suggested a likelihood that it may serve as link between the three systems.

[0004] In view of the potential therapeutic applications of agonists or antagonists of the sigma receptor, a great effort has been directed to find selective ligands. Thus, the prior art discloses different sigma receptor ligands.

[0005] International patent application WO 91/09594 generically describes a broad class of sigma receptor ligands some of which are 4-phenylpiperidine, -tetrahydro-pyridine or - piperazine compounds having an optionally substituted aryl or heteroaryl, alkyl, alkenyl, alkynyl, alkoxy or alkoxyalkyl substituent on the ring N-atom. The terms aryl and heteroaryl are defined by mention of a number of such substituents.

[0006] European patent application EP 0 414 289 A1 generically discloses a class of 1,2,3,4-tetrahydro-spiro[naph-thalene-1,4’-piperidine] and 1,4-dihydro-spiro[naphthalene-1,4’-piperidine] derivatives substituted at the piperidine N-atom with a hydrocarbon group alleged to have selective sigma receptor antagonistic activity. The term hydrocarbon, as defined in said patent, covers all possible straight chained, cyclic, heterocyclic, etc. groups. However, only compounds having benzyl, phenethyl, cycloalkyl methyl, furyl-or thienyl methyl or lower alkyl or alkenyl as the hydrocarbon substituent at the piperidine nitrogen atom are specifically disclosed. The compounds are stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM. 1-benzyl-1,2,3,4-tetrahydro-spiro [naphthalene-1 ^’-piperidine] is mentioned as a particularly preferred compound.

[0007] European patent application EP 0 445 974 A2 generically describes the corresponding spiro[indane-1,4’-pip-eridine] and spiro[benzocycloheptene-5,4’-piperidine] derivatives. Again the compounds are only stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM.

[0008] European patent application EP 0 431 943 A relates to a further extremely broad class of spiropiperidine compounds substituted at the piperidine N-atom and claimed to be useful as antiarrhythmics and for impaired cardiac pump function. The said application exemplifies several compounds, the majority of which contain an oxo and/or a sulfonylamino substituent in the spiro cyclic ring system. Of the remainder compounds, the main part has another polar substituent attached to the spiro nucleus and/or they have some polar substituent on the piperidine N-atom. No suggestion or indication of effect of the compounds on the sigma receptor is given.

[0009] Patent applications EP 518 805 A and WO 02/102387 describe sigma receptor ligands having piperidine or spiropiperidine structures.

[0010] With regard to the chemical structure of the compounds described in the present patent application, there are some documents in the prior art which disclose pyrazole derivatives characterized, among other things, for being sub- stituted by amino alkoxy groups in different positions of the pyrazole group.

[0011] Patent US 4,337,263 discloses 1-aryl-4-arylsulphonyl-3-amino propoxy-1H-pyrazoles, wherein the amino group can be constituted by an N-cycle group as morpholine, piperidine or pyrrolidine group. They are used as hypolipemiant or hypocholesteroleminant agents.

[0012] Patent FR 2301250 describes similar compounds as those mentioned above, such as 1,4-diaryl-3-aminoalkoxy pyrazoles, wherein the amino group comprises pyrrolidine, piperidine, hydroxypiperidine, morpholine or piperazine derivatives.

[0013] Patent application US2003/0144309 refers to pyrazoles with their 3 position substituted by a dimethylami-noethoxy group and present in their 4 position a pyrimidine group. They are used as inhibitors of JNK3, Lekor Src kinase activity.

[0014] International patent application WO 02/092573 describes substituted pirazole compounds as inhibitors of SRC and other protein kinases.

[0015] International patent application WO 2004/017961 discloses pyrazole compounds wherein the 3 position is substituted by an alkoxy group directly bounded to a cyclic amide, which are used for therapeutically treating and/or preventing a sex hormone related condition in a patient.

[0016] Patent US 6,492,529 describes pyrazole derivatives which are used for the treatment of inflammatory diseases. These compounds present in the 5 position a urea group, linked in some cases to a morpholine ethoxy group.

[0017] International patent application WO 04/016592 refers to pyrazole compounds for inhibiting protein prénylation which comprises in the 5 position, among others, an alkoxy group directly bonded to a cyclic amide.

[0018] However, none of these documents suggests the effect of these compounds on the sigma receptor.

[0019] WO 2006/021462 and WO 2007/098964 describe pyrazole derivatives as selective inhibitors of the sigma receptor. These compounds present in the 3 position an alkoxy group.

[0020] Also EP 1 829 866 A1 discloses pyrazoles for use in the treatment of sigma receptor-mediated diseases.

[0021] There is still a need to find compounds that have pharmacological activity towards the sigma receptor, being both effective and selective, and having good "drugability" properties, i.e. good pharmaceutical properties related to administration, distribution, metabolism and excretion.

BRIEF DESCRIPTION OF THE INVENTION AND THE FURTHER DISCLOSURE

[0022] The inventors of the present invention have surprisinglyfound afamily of structurally distinct pyrazole derivatives which are particularly selective inhibitors of the sigma receptor. The compounds present a pyrazole group which are characterized by the substitution at position 3 by an alkyl chain containing an amine at its end and optionally an intermediate oxa moiety.

[0023] The present invention relates to compounds as defined in claim 1.

[0024] One aspect of the further disclosure relates to a compound of general formula (I):

wherein R1 represents substituted or unsubstituted aromatic or non-aromatic heterocyclyl; substituted or unsubstituted aryl; or substituted or unsubstituted cycloalkyl; R2 and R3, identical or different, represent a hydrogen atom; F; Cl; Br; I; CF3; OH; SH; NH2; CN; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; a (C=0)-R7 group; a (C=0)-0-R8 group; a S(0)t-R9 group; or a (C=O)-NR10R11 group; R4 and R5, identical or different, represent a hydrogen atom; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; a (C=0)-R7 group; a (C=0)-0-R8 group; a S(0)t-R9 group; or a (C=O)-NR10R11 group; or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or nonaromatic heterocyclyl group; X represents an oxygen atom or a CH-R12 group wherein R12 is selected from H, CH3, SH, OH, NH2, CF3, Cl, F, Br, I, and CN; m is selected from 1,2,3 and 4; n is selected from 1,2,3 and 4; t is selected from 1,2 and 3; R7, R8, R9, R10 and R11, identical or different, represent a hydrogen atom; substituted or unsubstituted C^g alkyl; substituted or unsubstituted C2_6 alkenyl; substituted or unsubstituted C^g alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

[0025] Another aspect of this disclosure refers to the process for the preparation of a compound of formula (I) as defined above, or a salt, isomer or solvate thereof.

[0026] Another aspect of this disclosure refers to a medicament or pharmaceutical composition comprising at least one compound of formula (I) as defined above, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof and a pharmaceutically acceptable excipient.

[0027] Another aspect of this disclosure refers to a compound of formula (I) as defined above for use as a medicament, particularly for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition.

[0028] Another aspect of this disclosure refers to the use of a compound of formula (I) as defined above in the manufacture of a medicament for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition.

[0029] Another aspect of the present disclosure refers to a method for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition, the method comprising administering to the subject in need of such a treatment or prophylaxis a therapeutically effective amount of a compound of formula (I) as defined above.

[0030] In one embodiment, said sigma receptor-mediated disease or condition is selected from the group consisting of diarrhoea; lipoprotein disorders; migraine; obesity; elevated triglyceride levels; chylomicronemia; dysbetalipoproteine-mia; hyperlipoproteinemia; hyperlipidemia; mixed hyperlipidemia; hypercholesterolemia; lipoprotein disorders; hypertriglyceridemia; sporadic hypertriglyceridemia; inherited hypertriglyceridemia; dysbetalipoproteinemia; arthritis; hypertension; arrhythmia; ulcer; learning, memory and attention deficits; cognition disorders; neurodegenerative diseases; demyelinating diseases; addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive dyskinesia; ischemic stroke; epilepsy; stroke; stress; cancer; psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation; and autoimmune diseases.

[0031] In another embodiment, said sigma receptor-mediated disease or condition is selected from the group consisting of pain, preferably neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia. In another embodiment, the compound of formula (I) is used as a pharmacological tool.

[0032] These aspects and preferred embodiments thereof are additionally also defined in the claims.

DETAILED DESCRIPTION OF THE INVENTION AND THE FURTHER DISCLOSURE

[0033] the context of the present invention, the following terms have the meaning detailed below.

[0034] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of 1 to 12 carbon atoms, containing no unsaturation, and which is attached to the rest of the molecule by a single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc.

[0035] Preferred alkyl radicals have from 1 to 6 carbon atoms. If substituted by aryl, it corresponds to an "Arylalkyl" radical, such as benzyl or phenethyl. If substituted by heterocyclyl, it corresponds to a "Heterocyclylalkyl" radical. If substituted by cycloalkyl, it corresponds to a "Cycloalkylalkyl" radical.

[0036] "Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting of 2 to 12 carbon atoms, containing at least one unsaturation, and which is attached to the rest of the molecule by a single bond. Preferred alkenyl radicals have from 2 to 6 carbon atoms.

[0037] "Cycloalkyl" refers to a stable 3-to 10-membered monocyclic or bicyclic radical which is saturated or partially saturated, and which consist solely of carbon and hydrogen atoms, such as cyclohexyl or adamantyl. Unless otherwise stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents such as alkyl, halo, hydroxy, amino, cyano, nitro, alkoxy, carboxy, alkoxycarbonyl, etc.

[0038] "Aryl" refers to single and multiple aromatic ring radicals, including multiple ring radicals that contain separate and/or fused aryl groups. Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms, such as phenyl, naphthyl, indenyl.fenanthryloranthracyl radical. The aryl radical may be optionally substituted by one or more substituents such as hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino, aminoalkyl, acyl, alkoxycarbonyl, etc.

[0039] "Heterocyclyl" refers to a stable 3-to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, preferably a 4-to 8-membered ring with one or more heteroatoms, more preferably a 5-or 6-membered ring with one or more heteroatoms. It may be aromatic (i.e. "heteroaryl") or not aromatic. For the purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidised; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated or aromatic. Examples of such heterocycles include, but are not limited to, azepines, benzimidazole, benzothiazole, furán, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran, coumarine, morpholine; pyrrole, pyrazole, oxazole, isoxazole, triazole, imidazole, etc.

[0040] "Alkoxy" refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above having one or more (e.g., 1,2, 3 or 4) oxygen linkages and from 1 to about 12 carbon atoms or preferably 1 to about 6 carbon atoms, e. g., methoxy, ethoxy, propoxy, etc.

[0041] "Amino" refers to a radical of the formula -NH2, -NHRa or -NRaRb, optionally quaternized, e.g., methylamino, ethylamino, dimethylamino, diethylamino, propylamino, etc.

[0042] "Halogen", "halo" or "hal" refers to bromo, chloro, iodo orfluoro.

[0043] References herein to substituted groups in the compounds of the present invention refer to the specified moiety that may be substituted at one or more (e.g., 1,2, 3 or 4) available positions by one or more suitable groups, e. g., halogen such asfluoro, chloro, bromo and iodo; cyano; hydroxyl; nitro; azido; acyl, such as alkanoyl, e.g. a 01-6 alkanoyl group, and the like; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms and more preferably 1-3 carbon atoms; alkenyl and alkynyl groups including groups having one or more (e.g., 1,2, 3 or 4) unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms; alkoxy groups having one or more (e.g., 1, 2, 3 or 4) oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more (e.g., 1,2, 3 or 4) thioether linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more (e.g., 1, 2, 3 or 4) sulfinyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those moieties having one or more (e.g., 1,2, 3 or 4) sulfonyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkyl groups such as groups having one or more (e.g., 1,2, 3 or 4) N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; carbocylic aryl having 6 or more carbons, particularly phenyl or naphthyl and aralkyl such as benzyl. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.

[0044] The term "salt" must be understood as any form of an active compound used in accordance with this invention in which said compound is in ionic form or is charged and coupled to a counter-ion (a cation or anion) or is in solution. This definition also includes quaternary ammonium salts and complexes of the active molecule with other molecules and ions, particularly, complexes formed via ionic interactions. The definition includes in particular physiologically acceptable salts; this term must be understood as equivalent to "pharmacologically acceptable salts".

[0045] The term "pharmaceutically acceptable salts" in the context of this invention means any salt that is tolerated physiologically (normally meaning that it is not toxic, particularly, as a result of the counter-ion) when used in an appropriate manner for a treatment, applied or used, particularly, in humans and/or mammals. These physiologically acceptable salts may be formed with anions or acids and, in the context of this invention, are understood as being salts formed by at least one compound used in accordance with the invention - normally protonated, for example in nitrogen - such as a cation and at least one physiologically tolerated anion, particularly when used on humans and/or mammals. This definition specifically includes in the context of this invention a salt formed by a physiologically tolerated acid, i.e. salts of a specific active compound with physiologically tolerated organic or inorganic acids - particularly when used on humans and/or mammals. Examples of this type of salts are those formed with: hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.

[0046] The term "solvate" in accordance with this invention should be understood as meaning any form of the active compound in accordance with the invention in which said compound is bonded by a non-covalent bond to another molecule (normally a polar solvent), including especially hydrates and alcoholates, like for example, methanolate. A preferred solvate is the hydrate.

[0047] The compounds of the invention may be in crystalline form either as free compounds or as solvates and it is intended that both forms are within the scope of the present invention. Methods of solvation are generally known within the art. Suitable solvates are pharmaceutically acceptable solvates. In a particular embodiment the solvate is a hydrate.

[0048] Any compound that is a prodrug of a compound of formula (I) is also disclosed herein.

[0049] The term "prodrug" is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Examples of prodrugs include, but are not limited to, derivatives and metabolites of the compounds of formula I that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Preferably, prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by Burger "Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001, Wiley), "Design and Applications of Prodrugs" (H. Bundgaard ed., 1985, Harwood Academic Publishers) and Krogsgaard-Larsen et al. "Textbook of Drug design and Discovery" Taylor &amp; Francis (April 2002).

[0050] The compounds of the present invention represented by the above described formula (I) may include enantiomers depending on the presence of chiral centres or isomers depending on the presence of multiple bonds (e.g. Z, E). The single isomers, enantiomers ordiastereoisomers and mixtures thereof fall within the scope of the present invention.

[0051] Furthermore, any compound referred to herein may exist as tautomers. Specifically, the term tautomer refers to one of two or more structural isomers of a compound that exist in equilibrium and are readily converted from one isomeric form to another. Common tautomeric pairs are amine-imine, amide-imidic acid, keto-enol, lactam-lactim, etc. Unless otherwise stated, the compounds of the invention are also meant to include isotopically-labelled forms i.e. compounds which differ only in the presence of one or more isotopically-enriched atoms. For example, compounds having the present structures except for the replacement of at least one hydrogen atom by a deuterium or tritium, or the replacement of at least one carbon by 13C- or 14C-enriched carbon, or the replacement of at least one nitrogen by 15N-enriched nitrogen are within the scope of this invention.

[0052] The compounds of formula (I), or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I), or of its salts, solvates or prodrugs.

[0053] The term "pharmaceutically acceptable salts, solvates, prodrugs" refers to any pharmaceutically acceptable salt, ester, solvate, or any other compound which, upon administration to the recipient is capable of providing (directly or indirectly) a compound as described herein. However, it will be appreciated that non-pharmaceutically acceptable salts are also disclosed herein since those may be useful in the preparation of pharmaceutically acceptable salts. The preparation of salts, prodrugs and derivatives can be carried out by methods known in the art.

[0054] As used herein, the terms "treat", "treating" and "treatment" include the eradication, removal, reversion, alleviation, modification, or control of a sigma receptor mediated disease or condition.

[0055] As used herein, the terms "prevention", "preventing", "preventive", "prevent" and prophylaxis refer to the capacity of a compound of formula (I) to avoid, minimize or difficult the onset or development of a sigma receptor mediated disease or condition before its onset.

[0056] The term "pharmacological tool" refers to the property of compounds of the invention through which they are particularly selective ligands for Sigma receptors which implies that compound of formula (I), described in this invention, can be used as a model for testing other compounds as sigma ligands, ex. a radiactive ligands being replaced, and can also be used for modeling physiological actions related to sigma receptors.

[0057] In one embodiment, R1 in formula (I) above is selected from a 5-to 10 membered substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group which preferably contains N, O or S as ring member; a 5-to 10 membered substituted or unsubstituted aryl group; and a 5-to 10 membered substituted or unsubstituted cycloalkyl group.

[0058] In a preferred embodiment, R1 in formula (I) above is selected from substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphtyl, substituted or unsubstituted thiophene, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzo-furan, substituted or unsubstituted pyridine and substituted or unsubstituted quinoline.

[0059] In a still more preferred embodiment, R1 in formula (I) above is selected from the group consisting of: 2-thienyl, 3-thienyl, 2,5-dichloro-3-thienyl, 2,3-dichloro-5-thienyl, 2,3-dichloro-4-thienyl, 2-benzothienyl, 3-benzothienyl, 4-benzo-thienyl, 5-benzothienyl, 7-benzothienyl, 2-benzofuryl, 5-benzofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 5-quinolyl, 6-quinolyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, cyclopentyl and cyclohexyl.

[0060] In another preferred embodiment, R1 in formula (I) above is an a or ß naphthyl, preferably selected from the following aorß naphthyl groups: 7-hydroxy-2-naphtyl, 6-hydroxy-2-naphtyl, 5-hydroxy-2-naphtyl, 6-fluoro-2-naphtyl, 6-methoxy-2-naphtyl, 6-bromo-2-naphtyl, 6-hydroxymethyl-2-naphthyl, 6-fluoromethyl-2-naphthyl, 7-hydroxy-1 -naphtyl, 6-hydroxy-1-naphtyl, 5-hydroxy-1 -naphtyl, 5-fluoro-1-naphtyl, 5-bromo-1-naphtyl and 1-naphtyl.

[0061] In another embodiment, R2 and R3 in formula (I) are independently selected from H and substituted or unsubstituted 01-6 alkyl group, preferably methyl. More particular embodiments are those wherein R2 is methyl and R3 is H, or R2 and R3 are simultaneously H, or simultaneously methyl.

[0062] In a preferred embodiment, R4 and R5 form together with the nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group. More preferably, R4 and R5 form together a morpholine-4-yl group, a piperidine group, pyrrolidine group or a piperazine-4-yl group.

[0063] Preferred values for m and n are independently 1 and 2.

[0064] Further, X preferably represents an oxygen atom or a -CH2- group.

[0065] In additional preferred embodiments, the preferences described above for the different substituents are combined. The present disclosure is also directed to such combinations of preferred substitutions in the formula (I) above.

[0066] Particular individual compounds of the disclosure falling under formula (I) include the compounds listed below: 4-(2-((1 -(3,4-dichlorophenyl)-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(2-((5-methyl-1-(naphthalen-2-yl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-(1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)propyl)morpholine, 4-(3-(5-methyl-1-(naphthalen-2-yl)-1/-/-pyrazol-3-yl)propyl)morpholine, 4-(2-(2-(1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)ethoxy)ethyl)morpholine, 4-(2-((1-cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-(1 -cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)propyl)morpholine, 1-(3,4-dichlorophenyl)-5-methyl-3-((2-(pyrrolidin-1-yl)ethoxy)methyl)-1/-/-pyrazole, 1-(2-((1 -(3,4-dichlorophenyl)-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperidine, 1-(4-(2-((1-(3,4-d ich lorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, (2S,6R)-4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)-2,6-dimethylmorpholine, 4-(2-((5-methyl-1-(quinolin-3-yl)-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(4-(1-(3,4-dichlorophenyl)-5-methyl-1/-/-pyrazol-3-yl)butyl)morpholine, 4-(3-(5-methyl-1-(quinolin-3-yl)-1 /-/-pyrazol-3-yl)propyl)morpholine, 4-(2-((1-(3,4-dichlorophenyl)-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(2-((1-(3,4-dichlorophenyl)-4,5-dimethyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-(1 -(quinolin-3-yl)-1/-/-pyrazol-3-yl)propyl)morpholine, 4-(4-(1-(3,4-dichlorophenyl)-1 /-/-pyrazol-3-yl)butyl)morpholine, 4-(4-(5-methyl-1-(quinolin-3-yl)-1 /-/-pyrazol-3-yl)butyl)morpholine, 4-(3-((1 -cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)propyl)morpholine, 4-(2-((1 -cyclopentyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 1 -(4-(2-((1 -cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone hydrochloride, (3S,5R)-1 -(2-((1 -cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)-3,5-dimethylpiperazine hydrochloride, 4-(2-(2-(1-cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)ethoxy)ethyl)morpholine hydrochloride, 4-(2-((1 -cyclohexyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholine hydrochloride, 4-(2-((1 -cyclohexyl-4,5-dimethyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine hydrochloride, 1-(4-(2-((1-cyclohexyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-cyclohexyl-1/-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(4-((1-cyclohexyl-1/-/-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone, 1 -(4-(4-((1 -cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)butyl)piperazin-1 -yl)ethanone, 1 -(4-(3-((1 -cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(2-((1-(3,4-dichlorophenyl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, 1 -(4-(3-((1 -(3,4-dichlorophenyl)-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(4-((1-(3,4-dichlorophenyl)-1 /-/-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-(3,4-difluorophenyl)-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(3-((1 -(3,4-difluorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(2-((1-(3,4-difluorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, 1-(4-(2-((1-(3,4-d ifluorophenyl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, 4-(2-((1-(3,4-difluorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(2-((1-(3,4-d ifluorophenyl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-((1 -(3,4-d ifluorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)propyl)morpholine, 1-(4-(2-((1-cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, 1-(4-(2-((1-cyclohexyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-cyclohexyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, 1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-(3,4-d ich lorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, 1-(4-(2-((1-(3,4-dichlorophenyl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-(3,4-dichlorophenyl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, or a pharmaceutically acceptable salt, prodrug or solvate thereof.

[0067] Another aspect of the present disclosure relates to processes for the preparation of compounds of general formula (I) as described above.

[0068] Compounds corresponding to preferred embodiments according to general formula (la), (lb), (Ic) and (Id) could be prepared as follows:

Reaction scheme (I)

Reaction scheme (II)

Method A

Method B

Reaction scheme (III)

Process for preparing a compound of formula (la): [0069] Reaction of a compound of formula (II) with a compound of formula (III) in the presence of a base and a suitable solvent; where LG represents a leaving group that may be selected from a halide, e.g. bromide or chloride, or an arylsulfonyl group, e.g. mesylate, triflate, ortosylate, and the like. This reaction is conducted in a suitable solvent that will be a reaction-inert solvent, such as hydrocarbons like toluene; halogenated hydrocarbons, e.g. dichloromethane, chloroform; dipolar aprotic solvents such as acetonitrile, Ν,Ν-dimethylformamide (DMF), Ν,Ν-dimethylacetamide (DMA), dimethylsulfoxide (DMSO), hexamethylphosphoric triamide (HMPT); ethers such as tetrahydrofuran (THF), mixtures thereof with water, and the like. The base is strong enough to detract a hydrogen from the hydroxy group, for example an alkali of alkaline metal hydride such as lithium hydride or sodium hydride, or an alkali metal alkoxide such as sodium or potassium methoxide or ethoxide, potassium tert-butoxide, or potassium carbonate, triethylamine, pyridine, sodium iodide, cesium carbonate, etc.

[0070] Compounds of formula (III) are commercially available or obtained by methods known by the skilled in the art as for instance described in EP0529973.

[0071] Intermediates of formula (II) may be obtained as described in W02007079086, by reduction of a compound of formula (IV).

[0072] Pyrazole carboxylates of formula (IV) may be obtained as described in W02007079086, by reaction of a hydrazine derivative (V) with an 1,3-diketone of formula (VI) in a suitable solvent such as acetic acid.

[0073] Hydrazines (V) may be commercially available or obtained from a suitable nitro, amino or halo substituted derivative by methods generally known by the skilled in the art. (J. Am. Chem. Soc. 1998, 120, 6621; Angew. Chem., Int. Ed. 1998, 37, 2090).

[0074] 1,3-diketones (VI) may be obtained by a Claisen condensation between an alkyl ketone of formula CH3COR2 and diethyl oxalate.

Process for preparing a compound of formula (lb): [0075] Compounds of formula (lb) may be obtained by reduction of a compound of formula (IX) by methods known by the skilled in the art (Paul N. Rylander in "Hydrogenation Methods", Ed. Academic Press, 1990).

[0076] Compound of formula (IX) may be obtained by reaction of a compound of formula (VII) with a phosphonium salt of formula (VIII) in the presence of a base and a suitable solvent. The suitable solvent will be a reaction-inert solvent, such as hydrocarbons like toluene; halogenated hydrocarbons, e.g. dichloromethane, chloroform; dipolaraproticsolvents such as Ν,Ν-dimethylformamide (DMF), and the like; ethers such as tetrahydrofuran (THF), and the like; and the base, for example an alkali of alkaline metal hydride such as or sodium hydride, or an alkali metal alkoxide such as sodium or potassium methoxide or ethoxide, potassium tert-butoxide, or potassium carbonate, butyl lithium, triethylamine, pyridine, etc. (Chem. Rev. 1989, 89, 863-927; Top. Stereochem. 1994, 21, 1).

[0077] Phosphonium salts (VIII) are obtained by methods known by the skilled in the art from commercially available halides by reaction with triphenylphospine in the presence of a suitable solvent. (I. Gosney, A. G. Rowley in "Organophosphorous Reagents in Organic Synthesis", Ed. J. I. G. Cadogan, Academic Press, New York, 1979, Chpt 2; J Org. Chem. 1984, 49, 4293-4295 and references cited therein).

[0078] Compounds of formula (VII) may be obtained by oxidation of the above described intermediates (II) in the presence of a suitable oxidant agent such as Manganese (IV) oxide in a suitable solvent such as halogenated hydrocarbons, e.g. dichloromethane, chloroform. (Gabriel Tojo, Marcos Fernández in "Oxidation of Alcoholes to Aldehydes and Ketones: A Guide to Current Common Practice", Ed. Springer, 2006, Chpt 8).

Process for preparing a compound of formula (Ic):

According to method A: [0079] Reaction of a compound of formula (XII) with a compound of formula (III) in the presence of a base and a suitable solvent; where LG represents a leaving group that may be selected from a halide, e.g. bromide or chloride, or an arylsulfonyl group, e.g. mesylate, triflate, or tosylate, and the like. This reaction is conducted in a suitable solvent thatwill be a reaction-inert solvent, such as hydrocarbons like toluene; halogenated hydrocarbons, e.g. dichloromethane, chloroform; dipolar aprotic solvents such as acetonitrile, Ν,Ν-dimethylformamide (DMF), Ν,Ν-dimethylacetamide (DMA), dimethylsulfoxide (DMSO), hexamethylphosphoric triamide (HMPT); ethers such as tetrahydrofuran (THF), mixtures thereof with water, and the like. The base is strong enough to detract a hydrogen from the hydroxy group, for example an alkali of alkaline metal hydride such as lithium hydride or sodium hydride, or an alkali metal alkoxide such as sodium or potassium methoxide or ethoxide, potassium tert-butoxide, or potassium carbonate, triethylamine, pyridine, sodium iodide, cesium carbonate, etc.

[0080] Compounds of formula (III) are commercially available or obtained by methods known by the skilled in the art as for instance described in EP0529973.

[0081] Intermediates of formula (XII) may be obtained as described in W02007079086, by reduction of a compound of formula (XI).

[0082] Compounds of formula (XI) may be obtained by acid hydrolysis by methods known by the skilled in the art.

[0083] Compound of formula (X) may be obtained by reaction of a compound of formula (VII) with a phosphonium salt in the presence of a base and a suitable solvent. The suitable solvent will be a reaction-inert solvent, such as hydrocarbons like toluene; halogenated hydrocarbons, e.g. dichloromethane, chloroform; dipolar aprotic solvents such as Ν,Ν-dimethylformamide (DMF), and the like; ethers such as tetrahydrofuran (THF), and the like; and the base, for example an alkali of alkaline metal hydride such as or sodium hydride, or an alkali metal alkoxide such as sodium or potassium methoxide or ethoxide, potassium tert-butoxide, or potassium carbonate, butyl lithium, triethylamine, pyridine, etc. (Chem. Rev. 1989, 89, 863-927; Top. Stereochem. 1994, 21, 1).

[0084] Phosphonium salts are obtained by methods known by the skilled in the art from commercially available halides by reaction with triphenylphospine in the presence of a suitable solvent. (I. Gosney, A. G. Rowley in "Organophosphorous Reagents in Organic Synthesis", Ed. J. I. G. Cadogan, Academic Press, New York, 1979, Chpt 2; J Org. Chem. 1984, 49, 4293-4295 and references cited therein).

[0085] Compounds of formula (VII) may be obtained by oxidation of the above described intermediates (II) in the presence of a suitable oxidant agent such as manganese oxide in a suitable solvent such as halogenated hydrocarbons, e.g. dichloromethane, chloroform. (Gabriel Tojo, Marcos Fernández in "Oxidation ofAlcoholes to Aldehydesand Ketones: A Guide to Current Common Practice", Ed. Springer, 2006, Chpt 8).

[0086] Intermediates of formula (II) may be obtained as described in W02007079086, by reduction of a compound of formula (IV).

[0087] Pyrazole carboxylates of formula (IV) may be obtained as described in W02007079086, by reaction of a hydrazine derivative (V) with an 1,3-diketone of formula (VI) in a suitable solvent such as acetic acid.

[0088] Hydrazines (V) may be commercially available or obtained from a suitable nitro, amino or halo substituted derivative by methods generally known by the skilled in the art. (J. Am. Chem. Soc. 1998, 120, 6621; Angew. Chem., Int. Ed. 1998, 37, 2090).

[0089] 1,3-diketones (VI) may be obtained by a Claisen condensation between an alkyl ketone of formula CH3COR2 and diethyl oxalate.

According to method B: [0090] Reaction of a compound of formula (XVI) with a compound of formula (III) in the presence of a base and a suitable solvent; where LG represents a leaving group that may be selected from a halide, e.g. bromide or chloride, or an arylsulfonyl group, e.g. mesylate, triflate, or tosylate, and the like. This reaction is conducted in a suitable solvent thatwill be a reaction-inert solvent, such as hydrocarbons like toluene; halogenated hydrocarbons, e.g. dichloromethane, chloroform; dipolar aprotic solvents such as acetonitrile, Ν,Ν-dimethylformamide (DMF), Ν,Ν-dimethylacetamide (DMA), dimethylsulfoxide (DMSO), hexamethylphosphoric triamide (HMPT); ethers such as tetrahydrofuran (THF), mixtures thereof with water, and the like. The base is strong enough to detract a hydrogen from the hydroxy group, for example an alkali of alkaline metal hydride such as lithium hydride or sodium hydride, or an alkali metal alkoxide such as sodium or potassium methoxide or ethoxide, potassium tert-butoxide, or potassium carbonate, triethylamine, pyridine, sodium iodide, cesium carbonate, etc.

[0091] Compounds of formula (III) are commercially available or obtained by methods known by the skilled in the art as for instance described in EP0529973.

[0092] Intermediates of formula (XVI) may be obtained as described in W02007079086, by reduction of a compound of formula (XV).

[0093] Pyrazole carboxylates of formula (XV) may be obtained as described in W02007079086, by reaction of a hydrazine derivative (V) with methyl 3,5-dioxohexanoate of formula (XIV) in a suitable solvent such as MeOH.

[0094] Hydrazines (V) may be commercially available or obtained from a suitable nitro, amino or halo substituted derivative by methods generally known by the skilled in the art. (J. Am. Chem. Soc. 1998, 120, 6621; Angew. Chem., Int. Ed. 1998, 37, 2090).

[0095] Methyl 3,5-dioxohexanoate of formula (XIV) may be obtained by reaction of an commercially available dehy-droacetic acid (XIII) with magnesium in MeOH (Tetrahedron Letters 2010, 51,2741).

Process for preparing a compound of formula (Id): [0096] The procedure is the same as described above for compounds of formula (lb), using the appropriate compound (XVII).

[0097] During the processes described above the protection of sensitive groups or of reagents may be necessary and/or desirable. The introduction of conventional protective groups as well as their removal may be performed by methods well-known to those skilled in the art.

[0098] If the compounds of general formula (I) themselves are obtained inform of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractionalized crystallization with chiral reagents. If there are chiral centers the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. Solvates, preferably hydrates, of the compounds of general formula (I), of corresponding stereoisomers, or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.

[0099] The purification and isolation of the inventive compounds of general formula (I), of a corresponding stereoisomer, or salt, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.

[0100] It has been found that the compounds of general formula (I), stereoisomers thereof, corresponding salts and corresponding solvates have high affinity to sigma receptors, i.e. they are selective ligands for the sigma receptor and act as modulators, e.g. antagonists, inverse agonists or agonists, on these receptors.

[0101] The present disclosure further provides medicaments or pharmaceutical compositions comprising a compound of this disclosure, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomers thereof together with a pharmaceutically acceptable excipient, for administration to a patient, notably a human.

[0102] The term "excipient" refers to components of a drug compound other than the active ingredient (definition obtained from the European Medicines Agency- EMA). They preferably include a "carrier, adjuvant and/or vehicle". Carriers are forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions (U.S. National Library of Medicine. National Institutes of Health). Adjuvant is a substance added to a drug product formulation that affects the action of the active ingredient in a predictable way. Vehicle is an excipient or a substance, preferably without therapeutic action, used as a medium to give bulk for the administration of medicines (Stedman’s Medical Spellchecker, © 2006 Lippincott Williams &amp; Wilkins). Such pharmaceutical carriers, adjuvants or vehicles can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, excipients, disgregants, wetting agents or diluents. Suitable pharmaceutical carriers are described in "Remington’s Pharmaceutical Sciences" by E.W. Martin. The selection of these excipients and the amounts to be used will depend on the form of application of the pharmaceutical composition.

[0103] The medicament or pharmaceutical composition according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art. Therefore, the formulation in accordance with the invention may be adapted for topical or systemic application, particularly for dermal, transdermal, subcutaneous, intramuscular, intra-articular, intraperitoneal, intravenous, intra-arterial, intravesical, intraosseous, intracavernosal, pulmonary, buccal, sublingual, ocular, intravitreal, intranasal, percutaneous, rectal, vaginal, oral, epidural, intrathecal, intraventricular, intracerebral, intracerebroventricular, intracisternal, intraspinal, perispinal, intracranial, delivery via needles or catheters with or without pump devices, or other application routes.

[0104] In a preferred embodiment the pharmaceutical compositions are in oral form, either solid or liquid. Suitable dose forms for oral administration may be tablets, pills, caplets, gel caps, chewing gums, capsules, granules, drops, syrups or solutions and may contain conventional excipients known in the art such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycolate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.

[0105] The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art. The tablets may for example be prepared by wet or dry granulation and optionally coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

[0106] The pharmaceutical compositions may also be adapted for parenteral administration, such as sterile solutions, suspensions or reconstitutable dry preparations, aerosols or sprays in the appropriate unit dosage form. Adequate excipients can be used, such as bulking agents, buffering agents or surfactants.

[0107] The composition of the invention may be formulated as deposits in dissolved form or in patches, for percutaneous application.

[0108] Skin applications include ointments, gels, creams, lotions, suspensions or emulsions. Suitable form of rectal application is by means of suppositories.

[0109] The mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopoeias and similar reference texts.

[0110] In one embodiment of the invention it is preferred that compound of formula (I) is used in therapeutically effective amounts. The physician will determine the dosage of the present therapeutic agents which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the patient under treatment, the age of the patient, the type of disease or condition being treated. When the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. The compounds are useful in the same manner as comparable therapeutic agents and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents. Active compounds will typically be administered once or more times a day for example 1,2, 3 or 4 times daily, with typical total daily doses in the range of from 0.1 to 1000 mg/kg/day.

[0111] The compounds and compositions of this invention may be used with other drugs to provide a combination therapy. The other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or at different time.

[0112] The following examples are merely illustrative of certain embodiments of the invention and cannot be considered as restricting it in any way.

EXAMPLES

Example 1

Synthesis of 4-(2-{[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]methoxy}ethyl)morpholine 1.1 Synthesis of ethyl 1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate [0113]

[0114] Ethyl acetopyruvate (74 mg, 0.468 mmol) was added overa suspension of the starting material (100 mg, 0.468 mmol) in AcOH (5 mL) and the mixture was refluxed for 1 h. Then, it was allowed to cool to rt and diluyed with CH2CI2 (10 mL). The organic phase was washed with H20 (1x10 mL) and with NaOH ac. 10% (2x10 mL),, dried over Na2S04 anh., filtered and concentrated to dryness. The residue (171 mg) was purified by flash column chromatography in silica gel (21 % AcOEt/hexane), to yield 139 mg of the desired product (Rf= 0.6 (30% AcOEt/hexane), pale yellow solid, 99% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.62 (d, J = 2.4 Hz, 1 H, ArH); 7.54 (d, J = 8.3 Hz, 1 H, ArH); 7.32 (dd, J = 2.4 y 8.3 Hz, 1 H, ArH); 6.72 (s, 1 H, ArH); 4.39 (c, J = 6.8 Hz, 2H, CH2); 2.34 (s, 3H, CH3); 1.39 (t, J = 6.8 Hz, 3H, CH3). MS-EI+ m/z: 300.0 (M+1). 1.2 Synthesis of [1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]methanol [0115]

[0116] NaBH4 (104 mg, 2.76 mmol) was added over a suspension of the starting ester (551 mg, 1.84 mmol) in EtOH (12 mL). The mixture was refluxed (it is dissolved when refluxing) for 1 h, and more NaBH4 was added (104 mg, 2.76 mmol) then. It was refluxed for further 4 h, and it was allowed to cool to rt. It was poured into H20 (10 mL), and the aqueous layer was extracted with CH2CI2 (2x10 mL). The combined organic phases were washed with NH4CI ac. sat. (1x15 mL) and with H20 (1x15 mL), dried over Na2S04 anh., filtered and concentrated to dryness. The residue was purified by flash column chromatography in silica gel (42-60% AcOEt/hexane) to yield 354 mg of the desired product (Rf= 0.5 (10% MeOH/CH2CI2), yellow solid, 75% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.82 (d, J = 2.5 Hz, 1 H, ArH); 7.75 (d, J = 8.5 Hz, 1 H, ArH); 7.52 (m, 1 H, ArH); 6.43 (s, 1 H, ArH); 4.91 (s, 2H, CH2); 2.57 (s, 3H, CH3). 1.3 Synthesis of 4-(2-iodoethyl)morpholine [0117]

[0118] Nal (25.54 g, 170.40 mmol) was added over a suspension of the starting chloride (8.5 g, 56.80 mmol) in acetone (150 mL). The mixture was refluxed for 17 h, then it was allowed to cool to rt and filtered, washing with with CH2CI2 (3x100 mL). The filtrate was washed with H20 (3x250 mL), the organic phase was dried over Na2S04 anh., filtered and concentrated to dryness to yield 7.71 g of the desired iodide (Rf= 0.4 (40% AcOEt/hexane), oily yellow solid, 56% yield). NMR-1H (CDCI3, 250 MHz, δ): 3.64 (t, J = 4.7 Hz, 4H, CH2); 3.14 (t, J = 7.6 Hz, 2H, CH2) 2.65 (t, J = 7.6 Hz, 2H, CH2) 2.42 (t, J = 4.7Hz, 4H,CH2). 1.4 Synthesis of 4-(2-{[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]methoxy}ethyl)morpholine [0119]

[0120] NaH (60% in mineral oil, 25 mg, 0.622 mmol) was added over a solution of the starting alcohol (80 mg, 0.311 mmol) in THF (3 mL). The mixture was stirred at rt for 10 min h, and the starting iodide was added (225 mg, 0.933 mmol) in THF (2 mL). The mixture was refluxed for 2 h, then it was allowed to cool to rt and it was poured into NaHC03 ac. sat. (8.0 mL). CH2CI2 (10 mL) was added and the organic phase was separated. The aqueous phase was extracted with CH2CI2 (2x8 mL), and the combined organic phases were dried over Na2S04 anh., filtered and concentrated to dryness. The residue was purified by flash column chromatography in silica gel (3-5.2% MeOH/CH2CI2) to yield 114 mg of the desired product (Rf= 0.5 (10% MeOH/CH2CI2), cream solid, 99% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.59 (d, J=2.5Hz, 1 H, ArH); 7.52 (d, J= 8.6 Hz, 1 H, ArH); 7.32-7.27 (dd, J = 2.5 y 8.6 Hz, 1 H, ArH); 6.24 (s, 1 H, ArH); 4.54 (s, 2H, CH2); 3.73 (t, J = 4.6 Hz, 4H, CH2); 3.65 (t, J= 5.8 Hz, 2H, CH2); 2.62 (t, J= 5.8 Hz, 2H, CH2); 2.51 (t, J = 4.6 Hz, 4H, CH2); 2.35 (s, 3H, CH3). MS-EI+ m/z: 370.3, 372.3 (M+1).

Example 2

Synthesis of 4-(2-{[1-(2-naphthyl)-5-methyl-1H-pyrazol-3-yl]methoxy}ethyl)morpholine 2.1 Synthesis of 2-naphthylhydrazine hydrochloride [0121]

[0122] NaN02 (578 mg, 8.38 mmol) in H20 (1.2 mL) was slowly added (2 min of addition) over a suspension of 2-naphthylamine (800 mg, 5.59 mmol) in HCI ac. 6.0 M (6 mL) cooled in a H20-ice bath. The resulting solution was stirred in H20-ice bath for 1 h, and SnCI2 (3.71 g, 19.56 mol) was added slowly (5 min of addition). The resulting suspension was stirred in H20-ice bath for 3.5 h, and then filtered. The solid was successively washed with H20 at 0 °C (4x8 mL), with H20 at rt (1x8 mL), with Et20 at 0 °C (2x4 mL), with Et20/hexane (1:1,2x4 mL) and with hexane (2x5 mL). The solid was dried to yield 690 mg of the desired product (R/= 0.7 (40% AcOEt/hexane), cream solid, 63% yield). NMR-1H (DMSO-d6, 250 MHz, δ): 7.81 (m, 2H, ArH); 7.71 (d, J = 7.7 Hz, 1 H, ArH); 7.49-7.19 (m, 4H, ArH). MS-EI+ m/z: 159.1 (M-HCI+1). 2.2 Synthesis of ethyl 5-methyl-1-(2-naphthyl)-1H-pyrazole-3-carboxylate [0123]

[0124] Ethyl acetopyruvate (544 mg, 3.44 mmol) was added over a suspension of the starting hydrazine (670 mg, 3.44 mmol) in AcOH (5 mL). The resulting suspension was refluxed for 1 h, then it was allowed to cool to r.t. and diluted with CH2CI2 (15 mL). The organic phase was successively washed with H20 (2x20 mL), with NaOH ac. 10% (1x20 mL) and again with H20 (1x20 mL). The organic phase was dried over Na2S04 anh., filtered and concentrated to dryness. The residue was purified by flash column chromatography in silica gel (15-41% AcOEt/hexane), to yield 68 mg of isomer a (R/= 0.8 (20% AcOEt/hexane), orange solid, 7% yield) and 640 mg of isomer b (Rf= 0.6 (20% AcOEt/hexane), organge solid, 66% yield) NMR-1H isomer b (CDCI3, 250 MHz, δ): 7.95-7.84 (m, 4H, ArH); 7.60-7.51 (m, 3H, ArH); 6.78 (s, 1 H, ArH); 4.43 (c, J = 7.1 Hz, 2H, CH2); 2.38 (s, 3H, CH3); 1.40 (t, J = 7.1 Hz, 3H, CH3). NMR-1H isomer a (CDCI3, 250 MHz, δ): 7.91-7.85 (m, 4H, ArH); 7.53-7.48 (m, 3H, ArH); 6.86 (s, 1 H, ArH); 4.22 (c, J = 7.1 Hz, 2H, CH2); 2.39 (s, 3H, CH3); 1.20 (t, J = 7.1 Hz, 3H, CH3). 2.3 Synthesis of [5-methyl-1-(2-naphthyl)-1H-pyrazol-3-yl]methanol [0125]

[0126] NaBH4 (129 mg, 3.42 mmol) was added over a suspension of the starting ester (640 mg, 2.28 mmol) in EtOH (15 mL). The mixture was refluxed (it is dissolved when refluxing) for 1.5 h, and then more NaBH4 (640 mg, 2.28 mmol) was added. It was refluxed for another 4 h, and more NaBH4 (640 mg, 2.28 mmol) was added. After another 2.5 h, more NaBH4 (640 mg, 2.28 mmol) was added and it was refluxed for another 16 h. The reaction mixture was allowed to cool to rt and poured into H20 (10 mL). The aqueous phase was extracted with CH2CI2 (2x15 mL) and the combined organic phases were washed with NH4CI ac. sat. (2x30 mL), dried over Na2S04 anh., filtered and concentrated to dryness. The residue was purified by flash column chromatography in silica gel (60-70% AcOEt/hexane),to yield 309 mg of the desired product (R/= 0.2 (40% AcOEt/hexane), yellow solid, 57% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.96-7.96 (m, 4H, ArH); 7.61 (d, J= 1.9 Hz, 1 H, ArH); 7.56 (m, 2H, ArH); 6.25 (s, 1 H, ArH); 4.74 (sa, 2H, CH2); 2.39 (s, 3H, CH3). 2.4 Synthesis of 4-(2-{[1-(2-naphthyl)-5-methyl-1H-pyrazol-3-yl]methoxy}ethyl)morpholine [0127]

[0128] NaH (60% in mineral oil, 56 mg, 1.40 mmol) was added over a solution of the starting alcohol (167 mg, 0.70 mmol) in THF (6 mL). The mixture was stirred at rt for 5 min, and the starting iodide was added (354 mg, 1.47 mmol) in THF (2 mL). The reaction mixture was refluxed for 2 h, then it was allowed to cool to r.t. and poured into NaHC03 ac. sat. (15 mL). The aqueous phase was extracted with CH2CI2 (2x10 mL) and the combined organic phases were washed with NaHC03 ac. sat. (1x20 mL) and with H20 (1x10 mL), dried over Na2S04 anh., filtered and concentrated to dryness. The residue was purified by flash column chromatography in silica gel (4% MeOH/CH2CI2), to yield 176 mg of the desired product (Rf= 0.1 (5% MeOH/CH2CI2), orange oil, 71% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.89 (m, 4H, ArH); 7.61-7.50 (m, 3H, ArH); 6.28 (s, 1 H, ArH); 4.60 (s, 2H, CH2); 3.74 (t, J = 4.7 Hz, 4H, CH2); 3.69 (t, J = 5.8 Hz, 2H, CH2); 2.65 (t, J = 5.8 Hz, 2H, CH2); 2.53 (m, 4H, CH2); 2.39 (s, 3H, CH3). MS-EI+ m/z: 352.4 (M+1).

Example 3

Synthesis of 4-{3-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl] propyl}morpholine 3.1 Synthesis of ethyl 1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate [0129]

[0130] Ethyl acetopyruvate (74 mg, 0.468 mmol) was added overa suspension of the starting material (100 mg, 0.468 mmol) in AcOH (5 mL). The resulting mixture was refluxed for 1 h, then it was allowed to cool to rt and diluted with CH2CI2 (10 mL). The organic phase was washed with H20 (1x10 mL) and with NaOH ac. 10% (2x10 mL), dried over Na2S04 anh., filtered and concentrated to dryness. The residue (171 mg) was purified by flash column chromatography in silica gel (21% AcOEt/hexane), to yield 139 mg of the desired product (R/= 0.6 (30% AcOEt/hexane), pale yellow solid, 99% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.62 (d, J = 2.4 Hz, 1 H, ArH); 7.54 (d, J = 8.3 Hz, 1 H, ArH); 7.32 (dd, J = 2.4 y 8.3 Hz, 1 H, ArH); 6.72 (s, 1 H, ArH); 4.39 (c, J = 6.8 Hz, 2H, CH2); 2.34 (s, 3H, CH3); 1.39 (t, J = 6.8 Hz, 3H, CH3). MS-EI+m/z: 300.0 (M+1). 3.2 Synthesis of [1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]methanol [0131]

[0132] NaBH4 (104 mg, 2.76 mmol) was added over a suspension of the starting ester (551 mg, 1.84 mmol) in EtOH (12 mL). The mxiture was refluxed (it is dissolved when refluxing) for 1 h, and then more NaBH4 (104 mg, 2.76 mmol) was added. It was refluxed for another 4 h, and then it was allowed to cool to rt and poured into H20 (10 mL), The aqueous phase was extracted with CH2CI2 (2x10 mL) and the combined organic phases were washed with NH4CI ac. sat. (1x15 mL) and with H20 (1x15 mL), dried over Na2S04 anh., filtered y concentrated to dryness. The residue was purified by flash column chromatography in silica gel (42-60% AcOEt/hexane), to yield 354 mg of the desired product (Rf= 0.5 (10% MeOH/CH2CI2), yellow solid, 75% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.82 (d, J = 2.5 Hz, 1 H, ArH); 7.75 (d, J = 8.5 Hz, 1 H, ArH); 7.52 (m, 1 H, ArH); 6.43 (s, 1 H, ArH); 4.91 (s, 2H, CH2); 2.57 (s, 3H, CH3). 3.3 Synthesis of 1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazole-3-carbaldehyde [0133]

[0134] Mn02 (85% purity, 2.16 g, 21.10 mmol) was added over a solution of the starting alcohol (542 mg, 2.11 mmol) in CH2CI2 (30 mL). The mixture was refluxed for 16.5 h, and then it was allowed to cool to rt and filtered through Celite, washing with CH2CI2 (3x50 mL) and with 5% MeOH/CH2CI2 (1x40 mL). The filtrate was concentrated to dryness and purified by flash column chromatography in silica gel (20% AcOEt/hexane), to yield 403 mg of the desired product (R/= 0.5 (20% AcOEt/hexane), pale yellow solid, 75% yield). NMR-1H (CDCI3, 250 MHz, δ): 9.98 (s, 1 H, CHO); 7.65 (d, J = 2.5 Hz, 1 H, ArH); 7.61 (d, J = 8.5 Hz, 1 H, ArH); 7.36 (dd, J = 2.5 y 8.5 Hz, 1 H, ArH); 6.73 (s, 1 H, ArH); 2.39 (s, 3H, CH3). 3.4 Synthesis of 4-(2-iodoethyl)morpholine [0135]

[0136] Nal (25.54 g, 170.40 mmol) was added over a suspension of the starting chloride (8.5 g, 56.80 mmol) in acetone (150 mL). The mixture was refluxed for 17 h, then it was allowed to cool to r.t. and filtered, washing with with CH2CI2 (3x100 mL). The filtrate was washed with H20 (3x250 mL), the organic phase was dried over Na2S04 anh., filtered and concentrated to dryness to yield 7.71 g of the desired iodide (Rf= 0.4 (40% AcOEt/hexane), oily yellow solid, 56% yield). NMR-1H (CDCI3, 250 MHz, δ): 3.64 (t, J = 4.7 Hz, 4H, CH2); 3.14 (t, J = 7.6 Hz, 2H, CH2) 2.65 (t, J = 7.6 Hz, 2H, CH2) 2.42 (t, J = 4.7Hz, 4H,CH2). 3.5 Synthesis of (4-ethylmorpholine)(triphenyl)phosphonium iodide [0137]

[0138] PPh3 (3.26 g, 12.44 mmol) was added over a solution of the starting iodide (2.0 g, 8.29 mmol) in xylenes (15 mL). The mixture was refluxed for 16 h and then it was allowed to cool to rt. Toluene was added (8 mL) and it was stirred at rt for 2 h. The solid was filtered under vacuum, it was washed with Et20 (3x10 mL) and dried, to yield 3.96 g of the desired product (Rf= 0.1 (10% MeOH/CH2CI2), white solid, 95% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.93-7.83 (m, 15H, ArH); 3.84 (m, 2H, CH2); 3.29 (m, 4H, CH2) 2.59 (m, 2H, CH2) 2.30 (m, 4H, CH2). MS-EI+ m/z: 376.0 (M-l). 3.6 Synthesis of 4-{3-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]prop-2-enyl}morpholine [0139]

[0140] A portion of KO‘Bu (79 mg, 0.703 mmol) was added over a suspension of the phosphine salt (177 mg, 0.353 mmol) in THF (3 mL). It was stirred at r.t. for about 1 min (bright yellow suspension), and the starting aldehyde (108 mg, 0.423 mmol) in THF (3 mL) was added. The reaction mixture was stirred at r.t. for 1 h, and then diluted with CH2CI2 (10 mL) y H20 (10 mL) was added. The organic phase was separated and the aqueous phase was extracted with CH2CI2 (1x10 mL). The combined organic phases were dried over Na2S04 anh., filtered and concentrated to dryness. The residue was purified by three consecutive flash column chromatography in silica gel (4% MeOH/CH2CI2, 50% ace-tone/Hexane y CH2CI2/MeOH/NH4OH 98:2:1) to yield 45 mg of the desired product (R/= 0.5 (50% acetone/Hexane), pale yellow oil, 36% yield). NMR-1H (CDCI3, 250 MHz, δ) major isomer: 7.62 (d, J = 2.5 Hz, 1 H, ArH); 7.54 (d, J = 8.5 Hz, 1 H, ArH); 7.33 (dd, J = 2.5 y 8.5 Hz, 1 H, ArH); 6.45 (d, J = 11.8 Hz, 1 H, CH); 6.22 (s, 1 H, ArH); 5.84 (m, 1 H, CH); 3.74 (m, 4H, CH2); 3.46 (dd, J = 1.9 y 6.3 Hz, 2H, CH2); 2.53 (m, 4H, CH2); 2.37 (s, 3H, CH3). MS-EI+ m/z: 352.0, 354.0 (M). 3.7 Synthesis of 4-{3-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]propyl}morpholine [0141]

3 [0142] Pt02 (4 mg, 0.017 mmol) was added over a solution of a solution of the starting material (123 mg, 0.349 mmol) in MeOH (4 mL). The suspension was stirred at r.t. under H2 atmosphere (balloon) for 2 h, and then it was filtered through Celite, washing with MeOH (3x5 mL). The filtrate was concentrated to dryness and purified by flash column chromatography in silica gel (40% acetone/Hexane) to yield 79 mg of the desired product (Rf= 0.4 (50% acetone/Hexane), pale yellow oil, 64% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.59 (d, J = 2.5 Hz, 1 H, ArH); 7.50 (d, J = 8.8 Hz, 1 H, ArH); 7.29 (dd, J = 2.5 y 8.8 Hz, 1 H, ArH); 6.02 (s, 1 H, ArH); 3.72 (m, 4H, CH2); 2.64 (t, J = 7.7 Hz, 2H, CH2); 2.44 (m, 6H, CH2); 2.32 (s, 3H, CH3); 1.87 (m, 2H, CH2). MS-EI+ m/z: 351.8, 353.8 (M).

Example 4

Synthesis of 4-{3-[5-Methyl-1-(2-naphthyl)-1H-pyrazol-3-yl]propyl}morpholine 4.1 Synthesis of 2-naphthylhydrazine hydrochloride [0143]

[0144] NaN02 (578 mg, 8.38 mmol) in H20 (1.2 mL) was slowly added (2 min of addition) over a suspension of 2-naphthylamine (800 mg, 5.59 mmol) in HCI ac. 6.0 M (6 mL) cooled in a H20-ice bath. The resulting solution was stirred in H20-ice bath for 1 h, and SnCI2 (3.71 g, 19.56 mol) was slowly added (5 min of addition). The resulting suspension was stirred in H20-ice bath for 3.5 h, and then it was filtered. The solid was washed with H20 at 0 °C (4x8 mL), with H20 at rt (1x8 mL), with Et20 at 0 °C (2x4 mL), with Et20/hexane (1:1,2x4 mL) and with hexane (2x5 mL). The solid was dried to yield 690 mg of the desired product (Rf= 0.7 (40% AcOEt/hexane), cream solid, 63% yield). NMR-1H (DMSO-d6, 250 MHz, δ): 7.81 (m, 2H, ArH); 7.71 (d, J = 7.7 Hz, 1 H, ArH); 7.49-7.19 (m, 4H, ArH). MS-EI+ m/z: 159.1 (M-HCI+1). 4.2 Synthesis of ethyl 5-methyl-1-(2-naphthyl)-1 H-pyrazole-3-carboxylate [0145]

[0146] Ethyl acetopyruvate (544 mg, 3.44 mmol) was added over a suspension of the starting hydrazine (670 mg, 3.44 mmol) in AcOH (5 mL). The resulting suspension was refluxed for 1 h and then it was allowed to cool to rt and diluted with CH2CI2 (15 mL). The organic phase was washed with H20 (2x20 mL), with NaOH ac. 10% (1x20 mL) and again with H20 (1x20 mL). The organic phase was dried over Na2S04 anh., filtered and concentrated to dryness. The crude was purified by flash column chromatography in silica gel (15-41% AcOEt/hexane), to yield 68 mg of isomer a (R/= 0.8 (20% AcOEt/hexane), orange solid, 7% yield) and 640 mg of isomer b (R/= 0.6 (20% AcOEt/hexane), orange solid, 66% yield). NMR-1H isomer b (CDCI3, 250 MHz, δ): 7.95-7.84 (m, 4H, ArH); 7.60-7.51 (m, 3H, ArH); 6.78 (s, 1 H, ArH); 4.43 (c, J = 7.1 Hz, 2H, CH2); 2.38 (s, 3H, CH3); 1.40 (t, J = 7.1 Hz, 3H, CH3). NMR-1H isomer a (CDCI3, 250 MHz, δ): 7.91-7.85 (m, 4H, ArH); 7.53-7.48 (m, 3H, ArH); 6.86 (s, 1 H, ArH); 4.22 (c, J = 7.1 Hz, 2H, CH2); 2.39 (s, 3H, CH3); 1.20 (t, J = 7.1 Hz, 3H, CH3). 4.3 Synthesis of [5-methyl-1-(2-naphthyl)-1H-pyrazol-3-yl]methanol [0147]

[0148] NaBH4 (129 mg, 3.42 mmol) was added over a suspension of the starting ester (640 mg, 2.28 mmol) in EtOH (15 mL). The mixture was refluxed (it dissolves when refluxing) for 1.5 h, and then more NaBH4 (640 mg, 2.28 mmol) was added. It was refluxed for 4 h more, and more NaBH4 (640 mg, 2.28 mmol) was added. After 2.5 h, more NaBH4 (640 mg, 2.28 mmol) was added and it was refluxed for 16 h more. The reaction mixture was allowed to cool to r.t. and poured into H20 (10 mL). The aqueous phase was extracted with CH2CI2 (2x15 mL) and the combined organic phases were washed with NH4CI ac. sat. (2x30 mL), dried over Na2S04 anh., filtered and concentrated to dryness. The crude was purified by flash column chromatography in silica gel (60-70% AcOEt/hexane), to yield 309 mg of the desired product (Rf= 0.2 (40% AcOEt/hexane), yellow solid, 57% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.96-7.96 (m, 4H, ArH); 7.61 (d, J= 1.9 Hz, 1 H, ArH); 7.56 (m, 2H, ArH); 6.25 (s, 1 H, ArH); 4.74 (sa, 2H, CH2); 2.39 (s, 3H, CH3). 4.4 Synthesis of 5-methyl-1-(2-naphthyl)-1H-pyrazole-3-carbaldehyde [0149]

[0150] Mn02 (85% assay, 1.33 g, 12.97 mmol) was added over a solution of the starting alcohol (309 mg, 1.29 mmol) in CH2CI2 (10 mL). The mixture was refluxed for 3 h, and then it was allowed to cool to r.t. and filtered through Celite, washing with CH2CI2 (2x15 mL) and with 10% MeOH/CH2CI2 (3x15 mL). The filtrate was concentrated to dryness and purified by flash column chromatography in silica gel (20% AcOEt/hexane), to yield 218 mg of the desired product (Rf= 0.8 (40% AcOEt/hexane), pale yellow solid, 71% yield). NMR-1H (CDCI3, 250 MHz, δ): 10.04 (s, 1H, CHO); 7.94 (m, 4H, ArH); 7.60 (m, 3H, ArH); 6.77 (s, 1 H, ArH); 2.43 (s, 3H, CH3). 4.5 Synthesis of 4-{3-[5-methyl-1-(2-naphthyl)-1H-pyrazol-3-yl]prop-2-enyl}morpholine [0151]

[0152] A portion of KOtBu (69 mg, 0.6214 mmol) was added over a suspension of the phosphine salt (154 mg, 0.307 mmol) in THF (3 mL). It was stirred for about 1 min (bright yellow suspension), and the starting aldehyde (87 mg, 0.368 mmol) was added in THF (2 mL). The reaction mixture was stirred at rt for 45 min, and then NH4CI ac. sat. (10 mL) was added and extracted with AcOEt (1x10 mL). The organic phase was washed with NH4CI ac. sat. (2x10 mL) and with H20 (1x10 mL), dried over Na2S04 anh., filtered and concentrated to dryness. The crude was purified by flash column chromatography in silica gel (3% MeOH/CH2CI2) to yield 27 mg of the desired product (Rf= 0.2 (5% MeOH/CH2CI2), yellow oil, 26% yield). NMR-1H (CDCI3, 250 MHz, δ) major isomer: 7.88 (m, 4H, ArH); 7.62 (dd, J = 2.0 y 8.6 Hz, 1 H, ArH); 7.55 (m, 2H, ArH); 6.54 (d, J = 11.8 Hz, 1 H, CH); 6.27 (s, 1 H, ArH); 5.84 (m, 1 H, CH); 3.80 (m, 4H, CH2); 3.51 (m, 2H, CH2); 2.57 (m, 4H, CH2); 2.42 (s, 3H, CH3). 4.6 Synthesis of 4-{3-[5-Methyl-1-(2-naphthyl)-1H-pyrazol-3-yl]propyl}morpholine [0153]

[0154] The starting material (57 mg, 0.171 mmol) in MeOH (4 mL) was added over a suspension of Pd/C (10% by weight, 18 mg, 0.017 mmol) in MeOH (4 mL). The resulting suspension was stirred at rt under H2 atmosphere (balloon) for 2.5 h, and then it was filtered through Celite, washing with MeOH (3x5 mL). The filtrate was concentrated to dryness and purified by flash column chromatography in silica gel (3% MeOH/CH2CI2) to yield 46 mg of the desired product (R/= 0.15 (5% MeOH/CH2CI2), yellow oil, 81% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.84-7.94 (m, 4H, ArH); 7.59 (dd, J = 2.2 y 8.8 Hz, 1 H, ArH); 7.52 (m, 2H, ArH); 6.06 (s, 1 H, ArH); 3.74 (m, 4H, CH2); 2.71 (t, J= 7.7 Hz, 2H, CH2); 2.49 (m, 6H, CH2); 2.38 (s, 3H, CH3); 1.91 (m, 2H, CH2). MS-EI+ m/z: 335.9 (M+1).

Example 5

Synthesis of 4-(2-{2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]ethoxy} ethyl)morpholine 5.1. Synthesis of 1-(3,4-dichlorophenyl)-3-[2-methoxyvinyl]-5-methyl-1H-pyrazole [0155]

[0156] Over a suspension of(methoxymethyl)-triphenylphosphonium chloride (2.06 g, 6.0 mmol) in THF (10 mL) cooled at-35 °C in a C02-acetone bath, was slowly added n-BuLi (2.5 M in hexane, 2.4 mL, 6.0 mmol; 20 min of addition). The mixture was stirred, it was allowed to cool to -10 °C for 10 min, and the starting aldehyde (770 mg, 3.02 mmol) in THF (5.0 mL) was added slowly. The mixture was allowed to cool to r.t. and it was stirred for 15 h and poured into NH4CI ac. sat. (30 mL). The aqueous phase was extracted with AcOEt (1x30 mL). The organic phases were washed with NH4CI ac. sat. (1x30 mL) and with H20 (1x20 mL), dried over Na2S04 anh., filtered and concentrated to dryness. The crude was purified by flash column chromatography in Biotage SP1 (0-30% AcOEt/hexane), to yield 550 mg of the desired product (R/= 0.5 (20% AcOEt/hexane), yellow oil, 64% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.61 (d, J = 2.5 Hz, 1 H, ArH); 7.50 (d, J = 8.5 Hz, 1 H, ArH); 7.31 (dd, J = 8.5 and 2.5 Hz, 1 H, ArH); 7.17 (d, J= 13.2 Hz, 0.5H, CH); 6.59 (s, 0.5H, ArH); 6.22 (d, J= 6.9 Hz, 0.5H, CH); 6.13 (s, 0.5H, ArH); 5.78 (d, J= 13.2 Hz, 0.5H, CH); 5.45 (d, J= 6.9 Hz, 0.5H, CH); 3.80 (s, 1.5H, CH3); 3.68 (s, 1.5H, CH3); 2.35 (s, 1.5H, CH3); 2.33 (s, 1.5H, CH3). MS-EI+ m/z: 282.6, 285.3 (M+1). 5.2 Synthesis of [1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]acetaldehyde [0157]

[0158] H20 (1.0 mL) and HCI cone. (2.3 mL) was added over a solution of the starting ester (400 mg, 1.41 mmol) in MeOH (4.0 mL). The mixture was stirred at rt atmosphere for 16 h. NaOH ac. 50% was added to pH 7-8, and the aqueous phase was extracted with AcOEt (4x15 mL). The combined organic phases dried over Na2S04 anh., filtered and concentrated to dryness. The crude was purified by Biotage SP1 (0-30% AcOEt/hexane) to yield 106 mg of the desired product (R/= 0.3 (20% AcOEt/hexane), yellow oil, 28% yield). NMR-1H (CDCI3, 250 MHz, δ): 9.76 (t, J= 1.9 Hz, 1 H, CHO); 7.56 (d, J = 2.5 Hz, 1 H, ArH); 7.49 (d, J= 8.5 Hz, 1 H, ArH); 7.27 (dd, J = 8.5 and 2.5 Hz, 1 H, ArH); 6.11 (s, 1 H, ArH); 3.68 (d, J = 1.9 Hz, 2H, CH2); 2.31 (s, 3H, CH3). 5.3 Synthesis of 2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]ethanol [0159]

[0160] NaBH4 (92 mg, 2.43 mmol) was added over a solution of the starting aldehyde (219 mg, 0.814 mmol) in THF (5.0 mL) cooled in a H20-ice bath. The resulting solution was stirred in H20-ice bath for 30 min, and poured into NH4CI ac. sat. (15 mL). The aqueous phase was extracted with AcOEt (2x15 mL) and the combined organic phases were dried over Na2S04 anh., filtered and concentrated to dryness. The crude was purified by Biotage SP1 (0-60% AcOEt/hexane), to yield 110 mg of the desired product (R/= 0.3 (40% AcOEt/hexane), solid white, 50% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.58 (d, J = 2.5 Hz, 1 H, ArH); 7.52 (d, J = 8.5 Hz, 1 H, ArH); 7.30 (dd, J = 8.5 and 2.5 Hz, 1 H, ArH); 6.07 (s, 1 H, ArH); 3.91 (m, 2H, CH2); 2.87 (t, J = 5.9 Hz, 2H, CH2); 2.34 (s, 3H, CH3). 5.4 Synthesis of 4-(2-{2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]ethoxy} ethyl)morpholine [0161]

[0162] NaH (60% in mineral oil, 30 mg, 0.76 mmol) was added over a solution of the starting alcohol (104 mg, 0.383 mmol) in THF (5 mL). The mixture was stirred at rt for 10 min, and 4-(2-chloroethyl)morpholine (69 mg, 0.461 mmol) and Nal (74 mg, 0.493 mmol) were added. The reaction mixture was refluxed for 16 h, then it was allowed to cool to r.t. and poured into H20 (10 mL). The aqueous phase was extracted with AcOEt (3x15 mL) and the combined organic phases were dried over Na2S04 anh., filtered and concentrated to dryness. The residue was purified by Biotage SP1 (4-15% MeOH/CH2CI2), to yield 70 mg of the desired product (Rf= 0.2 (5% MeOH/CH2CI2), orange oil, 48% yield). NMR-1H (CDCI3, 250 MHz, δ): 7.59 (d, J = 2.5 Hz, 1 H, ArH); 7.51 (d, J = 8.5 Hz, 1 H, ArH); 7.29 (dd, J = 8.5 and 2.5 Hz, 1 H, ArH); 6.09 (s, 1 H, ArH); 3.76-3.68 (m, 6H, CH2); 3.62 (t, J = 5.8 Hz, 2H, CH2); 2.91 (t, J = 7.0 Hz, 2H, CH2); 2.59 (t, J= 5.8 Hz, 2H, CH2); 2.49 (m, 4H, CH2); 2.33 (s, 3H, CH3). MS-EI+ m/z: 384.2; 386.0 (M+1).

[0163] Further compounds of the invention are the examples shown in the following table:

(continued)

(continued)

(continued)

(continued)

(continued)

(continued)

(continued)

(continued)

(continued)

(continued)

BIOLOGICAL ACTIVITY

[0164] Some representative compounds of the invention were tested for their activity as sigma (sigma-1) inhibitors. The following protocol was followed: [0165] Brain membrane preparation and binding assays for the σ1-preceptor were performed as described (DeHaven-Hudkins et al., 1992) with some modifications. In brief, guinea pig brains were homogenized in 10 vols, (w/v) of Tris-HCI 50 mM 0.32 M sucrose, pH 7.4, with a Kinematica Polytron PT 3000 at 15000 r.p.m. for 30 s. The homogenate was centrifuged at 1000g for 10 min at 4°C and the supernatants collected and centrifuged again at 48000g for 15 min at 4°C. The pellet was resuspended in 10 volumes of Tris-HCI buffer (50 mM, pH 7.4), incubated at 37°C for 30 min, and centrifuged at 48000g for 20 min at 4°C. Following this, the pellet was resuspended in fresh Tris-HCI buffer (50 mM, pH 7.4) and stored on ice until use.

[0166] Each assay tube contained 10 μι of [3H](+)-pentazocine (final concentration of 0.5 nM), 900 μι of the tissue suspension to a final assay volume of 1 mL and a final tissue concentration of approximately 30 mg tissue net weight/mL. Non-specific binding was defined by addition of a final concentration of 1 μΜ haloperidol. All tubes were incubated at 37°C for 150 min before termination of the reaction by rapid filtration over Schleicher &amp; Schuell GF 3362 glass fibre filters [previously soaked in a solution of 0,5% polyethylenimine for at least 1 h]. Filters were then washed with four times with 4 mL of cold Tris-HCI buffer (50 mM, pH 7.4). Following addition of scintillation cocktail, the samples were allowed to equilibrate overnight. The amount of bound radioactivity was determined by liquid scintillation spectrometry using a Wallac Winspectral 1414 liquid scintillation counter. Protein concentrations were determined by the method of Lowry et al. (1951).

References: [0167] DeHaven-Hudkins, D. L., L.C. Fleissner, and F. Y. Ford-Rice, 1992, "Characterization of the binding of [3H](+)pentazocine to σ recognition sites in guinea pig brain", Eur. J. Pharmacol. 227, 371-378.

[0168] Lowry, O.H., N.J. Rosebrough, A.L. Farr, and R.J. Randall, 1951, Protein measurement with the Folin phenol reagent, J. Biol. Chem, 193, 265.

[0169] Some of the results obtained are shown in table (I).

Table (I)

(continued)

Claims

1. A compound of general formula (I):

(I) wherein R1 represents substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, wherein heterocyclyl is a stable 3-to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; substituted or unsubstituted aryl, wherein aryl is a group containing from 1 to 3 separated or fused rings and from 6 to 18 carbon ring atoms; or substituted or unsubstituted cycloalkyl, wherein cycloalkyl is a stable 3-to 10-membered monocyclic or bicyclic radical which is saturated or partially saturated; R2and R3are independently selected from H and substituted or unsubstituted 01-6 alkyl group, preferably methyl; wherein substitution in any of the substituted groups defined for R1, R2 and R3 is substitution at one or more available positions by one or more groups selected from halogen; cyano; hydroxyl; nitro; azido; acyl; carboxa-mido; alkyl groups having 1 to 12 carbon atoms; alkenyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkynyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to 12 carbon atoms; aryloxy; alkylthio groups having one or more thioether linkages and from 1 to 12 carbon atoms; alkylsulfinyl groups having one or more sulfinyl linkages and from 1 to 12 carbon atoms; alkylsulfonyl groups having one or more sulfonyl linkages and from 1 to 12 carbon atoms; aminoalkyl groups having one or more N atoms and from 1 to 12 carbon atoms; carbocylic aryl having 6 or more carbons; R4 and R5 together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, nonaromatic heterocyclyl, wherein heterocyclyl is a stable 5-or 6-membered ring radical which consists of carbon atoms and one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein substitution in the substituted heterocyclyl which R4 and R5 together form is substitution atone or more available positions by one or more groups selected from halogen; cyano; hydroxyl; nitro; azido; acyl; carboxa-mido; alkyl groups having 1 to 12 carbon atoms; alkenyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkynyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to 12 carbon atoms; alkylthio groups having one or more thioether linkages and from 1 to 12 carbon atoms; alkylsulfinyl groups having one or more sulfinyl linkages and from 1 to 12 carbon atoms; alkylsulfonyl groups having one or more sulfonyl linkages and from 1 to 12 carbon atoms; aminoalkyl groups having one or more N atoms and from 1 to 12 carbon atoms; X represents an oxygen atom or a CH-R12 group wherein R12 is selected from H, CH3, SH, OH, NH2, CF3, Cl, F, Br, I, and CN; m is selected from 1 and 2; n is selected from 1,2,3 and 4; or a pharmaceutically acceptable salt, enantiomer, diastereoisomer or solvate thereof. 2. The compound according to claim 1, wherein R1 is selected from substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted thiophene, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzofuran, substituted or unsubstituted pyridine and substituted or unsubstituted quinoline; wherein substitution in any of the defined substituted groups is as defined in claim 1. 3. The compound according to claim 2, wherein R1 is selected from the group consisting of: 2-thienyl, 3-thienyl, 2,5-dichloro-3-thienyl, 2,3-dichloro-5-thienyl, 2,3-dichloro-4-thienyl, 2-benzothienyl, 3-benzothienyl, 4-benzothienyl, 5-benzothienyl, 7-benzothienyl, 2-benzofuryl, 5-benzofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 5-quinolyl, 6-quinolyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, cyclopentyl, cyclohexyl, 7-hydroxy-2-naphthyl, 6-hy-droxy-2-naphthyl, 5-hydroxy-2-naphthyl, 6-fluoro-2-naphthyl, 6-methoxy-2-naphthyl, 6-bromo-2-naphthyl, 6-hy-droxymethyl-2-naphthyl, 6-fluoromethyl-2-naphthyl, 7-hydroxy-1-naphthyl, 6-hydroxy-1 -naphthyl, 5-hydroxy-1-naphthyl, 5-fluoro-1-naphthyl, 5-bromo-1 -naphthyl and 1-naphthyl. 4. The compound according to any of the preceding claims, wherein R2 is methyl and R3 is H, or R2 and R3 are simultaneously H or methyl. 5. The compound according to any of the preceding claims, wherein R4 and R5 form together a morpholine-4-yl group, a piperidine group, pyrrolidine group ora piperazine-4-yl group. 6. The compound according to any of the preceding claims, wherein n represents 1 or 2. 7. A compound according to any of the preceding claims selected from the group consisting of: 4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(2-((5-methyl-1-(naphthalen-2-yl)-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-(1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)propyl)morpholine, 4-(3-(5-methyl-1-(naphthalen-2-yl)-1 /-/-pyrazol-3-yl)propyl)morpholine, 4-(2-(2-(1-(3,4-dichlorophenyl)-5-methyl-1 /-/-pyrazol-3-yl)ethoxy)ethyl)morpholine, 4-(2-((1 -cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-(1-cyclohexyl-5-methyl-1 H-pyrazol-3-yl)propyl)morpholine, 1-(3,4-dichlorophenyl)-5-methyl-3-((2-(pyrrolidin-1-yl)ethoxy)methyl)-1H-pyrazole, 1-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperidine, 1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, (2S,6R)-4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)-2,6-dimethylmorpholine, 4-(2-((5-methyl-1-(quinolin-3-yl)-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(4-(1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yl)butyl)morpholine, 4-(3-(5-methyl-1-(quinolin-3-yl)-1 H-pyrazol-3-yl)propyl)morpholine, 4-(2-((1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(2-((1-(3,4-dichlorophenyl)-4,5-dimethyl-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-(1-(quinolin-3-yl)-1 H-pyrazol-3-yl)propyl)morpholine, 4-(4-(1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)butyl)morpholine, 4-(4-(5-methyl-1-(quinolin-3-yl)-H-pyrazol-3-yl)butyl)morpholine, 4-(3-((1-cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)propyl)morpholine, 4-(2-((1-cyclopentyl-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine, 1 -(4-(2-((1 -cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone hydrochloride, (3S,5R)-1-(2-((1-cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)-3,5-dimethylpiperazine hydrochloride, 4-(2-(2-(1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)ethoxy)ethyl)morpholine hydrochloride, 4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine hydrochloride, 4-(2-((1-cyclohexyl-4,5-dimethyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine hydrochloride, 1-(4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-cyclohexyl-1 H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(4-((1-cyclohexyl-1 H-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone, 1-(4-(4-((1-cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(2-((1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone 1-(4-(3-((1 -(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(4-((1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-(3,4-difluorophenyl)-1 H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(3-((1-(3,4-difluorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, 1-(4-(2-((1-(3,4-difluorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone, 4-(2-((1-(3,4-difluorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(2-((1-(3,4-difluorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)morpholine, 4-(3-((1-(3,4-difluorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)propyl)morpholine, 1-(4-(2-((1-cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-cyclohexyl-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, 1-(4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, 1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, 1-(4-(2-((1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, 1-(4-(2-((1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, or a pharmaceutically acceptable salt or solvate thereof. 8. A process for the preparation of a compound of formula (I) as defined in any of claims 1 to 7, or a salt, enantiomer, diastereoisomer or solvate thereof, which is selected from one of the following: a) a process which comprises the reaction of a compound of formula (II)

in which R2 and R3 are as defined in claim 1, with a compound of formula (III)

in which R4, R5 and n are as defined in claim 1 and LG represents a leaving group; b) a process which comprises the oxidation of a compound of formula (II) to afford a compound of formula (VII)

in which R^ R2 and R3 are as defined in claim 1, followed by the reaction of the compound of formula (VII) with a phosphonium salt of formula (VIII)

in which R4, R5 and n are as defined in claim 1, to afford a compound of formula (IX)

in which R^ R2, R3, R4, R5 and n are as defined in claim 1, and reduction of the compound of formula (IX); c) a process which comprises the oxidation of a compound of formula (II) to afford a compound of formula (VII)

in which R2 and R3 are as defined in claim 1, followed by the reaction of the compound of formula (VII) with a suitable phosphonium salt and subsequent acid hydrolysis to afford a compound of formula (XI)

in which R^ R2, R3 and m are as defined in claim 1, reduction of the compound of formula (XI) and subsequent reaction with a compound of formula (III)

in which R4, R5 and n are as defined in claim 1 and LG represents a leaving group; d) a process which comprises reaction of 3-acetyl-6-methyl-pyran-2,4-dione with magnesium and subsequent reaction with a compound of formula (V):

in which R1 is as defined in claim 1, to afford a compound of formula (XV)

in which R1 is as defined in claim 1, and reduction of the compound of formula (XV) and subsequent reaction with a compound of formula (III)

in which R4, R5 and n are as defined in claim 1 and LG represents a leaving group; e) a process which comprises the oxidation of a compound of formula (II) to afford a compound of formula (VII)

in which R^ R2 and R3 are as defined in claim 1, followed by the reaction of the compound of formula (VII) with a phosphonium salt of formula (XVII)

in which R4, R5, m and n are as defined in claim 1, to afford a compound of formula (XVIII)

in which R^ R2, R3, R4, R5, m and n are as defined in claim 1, and reduction of the compound of formula (XVIII). 9. A medicament comprising at least one compound offormula (I) as defined in any of claims 1 to 7, ora pharmaceutically acceptable salt, enantiomer, diastereoisomer or solvate thereof and a pharmaceutically acceptable excipient. 10. Compound offormula (I) as defined in any of claims 1 to 7 for use as a medicament. 11. Compound for use according to claim 10, wherein the medicament is for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition, wherein the disease or condition comprises diarrhea; lipoprotein disorders; migraine; obesity; elevated triglyceride levels; chylomicronemia; dysbetalipoproteinemia; hyperlipoproteinemia; hyperlipidemia; mixed hyperlipidemia; hypercholesterolemia; hypertriglyceridemia; sporadic hypertriglyceridemia; inherited hypertriglyceridemia; dysbetalipoproteinemia; arthritis; hypertension; arrhythmia; ulcer; learning, memory and attention deficits; cognition disorders; neurodegenerative diseases; demyelinating diseases; addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive dyskinesia; ischemic stroke; epilepsy; stroke; stress; cancer; psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation; and autoimmune diseases. 12. Compound for use according to claim 10, wherein the medicament is for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition, wherein the disease or condition comprises pain, preferably neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia.

Patentansprüche 1. Verbindung der allgemeinen Formel (I):

(I) worin R1 darstellt: ein substituiertes oder unsubstituiertes, aromatisches oder nicht-aromatisches Heterocyclyl, wobei das Heterocyclyl ein stabiles, 3- bis 15-gliedriges Ring-Radikal ist, welches aus Kohlenstoffatomen und aus einem bis fünf Heteroatomen besteht, ausgewählt aus der Gruppe bestehend aus Stickstoff, Sauerstoff und Schwefel; substituiertes oder unsubstituiertes Aryl, wobei das Aryl eine Gruppe ist, welche 1 bis 3 getrennte oder kondensierte Ringe und 6 bis 18 Ring-Kohlenstoffatome enthält; oder substituiertes oder unsubstituiertes Cycloalkyl, wobei das Cycloalkyl ein stabiles, 3- bis 10-gliedriges, monocyclisches oder bicyclisches Radikal ist, welches gesättigt oder teilweise gesättigt ist; R2 und R3 in unabhängigerWeise ausgewählt sind unter H und substituierten oder unsubstituierten C^g-Al-kylgruppen, vorzugsweise Methyl; wobei eine Substitution an irgendeiner derfür R1, R2 und R3 definierten substituierten Gruppen eine Substitution ist an einer oder mehreren verfügbaren Positionen durch eine oder mehrere Gruppen, welche ausgewählt sind unter: Halogen, Cyano, Hydroxyl, Nitro, Azido, Acyl, Carboxamido, Alkylgruppen mit 1 bis 12 Kohlenstoffatomen; Alkenylgruppen mit einer oder mehreren ungesättigten Bindungen und 2 bis 12 Kohlenstoffatomen, Alkinyl-gruppen mit einer oder mehreren ungesättigten Bindungen und 2 bis 12 Kohlenstoffatomen; Alkoxygruppen mit einer oder mehreren Sauerstoffverknüpfungen und 1 bis 12 Kohlenstoffatomen; Aryloxy; Alkylthiogruppen mit einer oder mehreren Thioether-Verknüpfungen und 1 bis 12 Kohlenstoffatomen; Alkylsulfinylgruppen mit einer oder mehreren Sulfinylverknüpfungen und 1 bis 12 Kohlenstoffatomen; Alkylsulfonylgruppen mit einer oder mehreren Sulfonylverknüpfungen und 1 bis 12 Kohlenstoffatomen; Aminoalkylgruppen mit einem oder mehreren N-Atomen und 1 bis 12 Kohlenstoffatomen; Arylcarbonsäuren mit 6 oder mehr Kohlenstoffatomen; R4 und R5 zusammen, mit dem Stickstoffatom, an welches sie gebunden sind, ein substituiertes oder unsubstituiertes, nicht-aromatisches Heterocyclyl bilden, wobei das Heterocyclyl ein stabiles, 5- oder 6-gliedriges Ring-Radikal ist, welches aus Kohlenstoffatomen und aus einem oder mehreren Heteroatomen besteht, ausgewählt aus der Gruppe bestehend aus Stickstoff, Sauerstoff und Schwefel; wobei eine Substitution im substituierten Heterocyclyl, welches R4 und R5 zusammen bilden, eine Substitution ist an einer oder mehreren verfügbaren Positionen durch eine oder mehrere Gruppen, welche ausgewählt sind unter Halogen; Cyano; Hydroxyl; Nitro; Azido; Acyl; Carboxamido; Alkylgruppen mit 1 bis 12 Kohlenstoffatomen; Alkenylgruppen mit einer oder mehreren ungesättigten Bindungen und 2 bis 12 Kohlenstoffatomen; Alkinyl-gruppen mit einer oder mehreren ungesättigten Bindungen und 2 bis 12 Kohlenstoffatomen; Alkoxygruppen mit einer oder mehreren Sauerstoffverknüpfungen und 1 bis 12 Kohlenstoffatomen; Alkylthiogruppen mit einer oder mehreren Thioether-Verknüpfungen und 1 bis 12 Kohlenstoffatomen; Alkylsulfinylgruppen mit einer oder mehreren Sulfinylverknüpfungen und 1 bis 12 Kohlenstoffatomen; Alkylsulfonylgruppen mit einer oder mehreren Sulfonylverknüpfungen und 1 bis 12 Kohlenstoffatomen; Aminoalkylgruppen mit einem oder mehreren N-Ato- men und 1 bis 12 Kohlenstoffatomen; X ein Sauerstoffatom oder eine CH-R12-Gruppe repräsentiert, worin R12 ausgewählt ist unter H, CH3, SH, OH, NH2, CF3, Cl, F, Br, I und CN; m ausgewählt ist unter 1 und 2; n ausgewählt ist unter 1,2, 3 und 4; oderein pharmazeutisch zulässiges Salz, Enantiomer, Diastereomer oder Solvat davon. 2. Zusammensetzung nach Anspruch 1, wobei R1 ausgewählt ist unter substituiertem oder unsubstituiertem Cyclo-pentyl, substituiertem oder unsubstituiertem Cyclohexyl, substituiertem oder unsubstituiertem Phenyl, substituiertem oder unsubstituiertem Naphthyl, substituiertem oder unsubstituiertem Thiophen, substituiertem oder unsubstituiertem Benzothiophen, substituiertem oder unsubstituiertem Benzofuran, substituiertem oder unsubstituiertem Pyridin und substituiertem oder unsubstituiertem Chinolin; wobei eine Substitution an irgendeiner der definierten substituierten Gruppen von einer Art ist, wie sie in Anspruch 1 definiert wurde. 3. Verbindung nach Anspruch 2, wobei R1 ausgewählt ist aus der Gruppe bestehend aus: 2-Thienyl, 3-Thienyl, 2,5-Dichlor-3-thienyl, 2,3-Dichlor-5-thienyl, 2,3-Dichlor-4-thienyl, 2-Benzothienyl, 3-Benzothienyl, 4-Benzothienyl, 5-Benzothienyl, 7-Benzothienyl, 2-Benzofuryl, 5-Benzofuryl, 2-Pyridyl, 3-Pyridyl, 4-Pyridyl, 2-Chinolyl, 3-Chinolyl, 5-Chinolyl, 6-Chinolyl, 3,4-Difluorphenyl, 3,4-Dichlorphenyl, Cyclopentyl, Cyclohexyl, 7-Hydroxy-2-naphthyl, 6-Hydro-xy-2-naphthyl, 5-Hydroxy-2-naphthyl, 6-Fluor-2-naphthyl, 6-Methoxy-2-naphthyl, 6-Brom-2-naphthyl, 6-Hydroxyme-thyl-2-naphthyl, 6-Fluormethyl-2-naphthyl, 7-Hydroxy-1-naphthyl, 6-Hydroxy-1-naphthyl, 5-Hydroxy-1-naphthyl, 5-Fluor-1-naphthyl, 5-Brom-1-naphthyl und 1-Naphthyl. 4. Verbindung nach einem der vorhergehenden Ansprüche, wobei R2 Methyl ist und R3 H ist, oder R2 und R3 sind gleichzeitig H oder Methyl. 5. Verbindung nach einem der vorhergehenden Ansprüche, wobei R4 und R5 zusammen eine Morpholin-4-yl-Gruppe bilden, eine Piperidin-Gruppe, eine Pyrrolidin-Gruppe odereine Piperazin-4-yl-Gruppe. 6. Verbindung nach einem der vorhergehenden Ansprüche, wobei n 1 oder 2 repräsentiert. 7. Verbindung nach einem der vorhergehenden Ansprüche, ausgewählt aus der Gruppe bestehend aus: 4-(2-((1 -(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(2-((5-Methyl-1-(naphthalin-2-yl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(3-(1-(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)propyl)morpholin, 4-(3-(5-Methyl-1-(naphthalin-2-yl)-1 /-/-pyrazol-3-yl)propyl)morpholin, 4-(2-(2-(1-(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)ethoxy)ethyl)morpholin, 4-(2-((1-Cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(3-(1-Cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)propyl)morpholin, 1-(3,4-Dichlorphenyl)-5-methyl-3-((2-(pyrrolidin-1-yl)ethoxy)methyl)-1/-/-pyrazol, 1-(2-((1 -(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperidin, 1-(4-(2-((1-(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanon, (2S,6R)-4-(2-((1-(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)-2,6-dimethylmorpholin, 4-(2-((5-Methyl-1-(chinolin-3-yl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(4-(1-(3,4-Dichlorphenyl)-5-methyl-1/-/-pyrazol-3-yl)butyl)morpholin, 4-(3-(5-Methyl-1-(chinolin-3-yl)-1/-/-pyrazol-3-yl)propyl)morpholin, 4-(2-((1-(3,4-Dichlorphenyl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(2-((1-(3,4-Dichlorphenyl)-4,5-dimethyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(3-(1-(Chinolin-3-yl)-1 /-/-pyrazol-3-yl)propyl)morpholin, 4-(4-(1-(3,4-Dichlorphenyl)-1 /-/-pyrazol-3-yl)butyl)morpholin, 4-(4-(5-Methyl-1-(chinolin-3-yl)-1/-/-pyrazol-3-yl)butyl)morpholin, 4-(3-((1-Cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)propyl)morpholin, 4-(2-((1 -Cyclopentyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)morpholin 1 -(4-(2-((1 -Cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanonhydrochlorid (3S,5R)-1-(2-((1-Cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)-3,5-dimethylpiperazinhydrochlorid, 4-(2-(2-(1 -Cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)ethoxy)ethyl)morpholinhydroch lórid, 4-(2-((1-Cyclohexyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholinhydrochlorid, 4-(2-((1 -Cyclohexyl-4,5-dimethyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholinhydrochlorid, 1-(4-(2-((1-Cyclohexyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanon, 1-(4-(3-((1-Cyclohexyl-1/-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanon, 1-(4-(4-((1-Cyclohexyl-1/-/-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanon, 1 -(4-(4-((1 -Cyclohexyl-5-methyl-1/-/-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanon, 1 -(4-(3-((1 -Cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanon, 1-(4-(2-((1 -(3,4-Dichlorphenyl)-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanon 1-(4-(3-((1-(3,4-Dichlorphenyl)-1/-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanon 1-(4-(4-((1-(3,4-Dichlorphenyl)-1/-/-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanon, 1-(4-(3-((1 -(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanon, 1-(4-(3-((1-(3,4-Difluorphenyl)-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanon, 1-(4-(3-((1-(3,4-Difluorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanon, 1-(4-(2-((1-(3,4-Difluorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanon, 1-(4-(2-((1-(3,4-Difluorphenyl)-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanon, 4-(2-((1 -(3,4-Difluorphenyl)-5-methyl-1/-/-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(2-((1 -(3,4-Difluorphenyl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholin, 4-(3-((1-(3,4-Difluorphenyl)-5-methyl-1/-/-pyrazol-3-yl)methoxy)propyl)morpholin, 1-(4-(2-((1-Cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-on, 1 -(4-(2-((1 -Cyclohexyl-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-on, 1-(4-(2-((1-Cyclohexyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-on, 1-(4-(2-((1-Cyclohexyl-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-on, 1-(4-(2-((1 -(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-on, 1-(4-(2-((1 -(3,4-Dichlorphenyl)-5-methyl-1 /-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-on, 1-(4-(2-((1-(3,4-Dichlorphenyl)-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-on, 1-(4-(2-((1-(3,4-Dichlorphenyl)-1/-/-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-on, oder ein pharmazeutisch zulässiges Salz oder Solvat davon. 8. Verfahren zur Herstellung einer Verbindung der Formel (I) wie definiert in einem der Ansprüche 1 bis 7, oder ein Salz, Enantiomer, Diastereomer oder Solvat davon, wobei das Verfahren ausgewählt ist unter einem derfolgenden: a) ein Verfahren, umfassend die Reaktion einer Verbindung der Formel (II)

worin R2 und R3 definiert sind wie in Anspruch 1, mit einer Verbindung der Formel (III)

worin R4, R5 und n definiert sind wie in Anspruch 1 und LG eine Abgangsgruppe darstellt; b) ein Verfahren, umfassend die Oxidation einer Verbindung der Formel (II), um eine Verbindung der Formel (VII) zu liefern

worin R2 und R3 definiert sind wie in Anspruch 1, gefolgt von der Reaktion der Verbindung der Formel (VII) mit einem Phosphoniumsalz der Formel (VIII)

worin R4, R5 und n definiert sind wie in Anspruch 1, um eine Verbindung der Formel (IX) zu liefern

worin R1, R2, R3, R4, R5 und n definiert sind wie in Anspruch 1, und Reduktion der Verbindung der Formel (IX); c) ein Verfahren, welches die Oxidation einer Verbindung der Formel (II) umfasst, um eine Verbindung der Formel (VII) zu liefern

worin R^ R2 und R3 definiert sind wie in Anspruch 1, gefolgt von der Reaktion der Verbindung der Formel (VII) mit einem geeigneten Phosphoniumsalz und anschließender saurer Flydrolyse, um eine Verbindung der Formel (XI) zu liefern

worin R2, R3 und m definiert sind wie in Anspruch 1, Reduktion der Verbindung der Formel (XI) und anschließender Reaktion mit einer Verbindung der Formel (III)

worin R4, R5 und n definiert sind wie in Anspruch 1 und LG eine Abgangsgruppe darstellt; d) ein Verfahren, welches die Reaktion von 3-Acetyl-6-methylpyran-2,4-dion mit Magnesium und anschließender

Reaktion mit einer Verbindung der Formel (V) umfasst:

worin R1 definiert ist wie in Anspruch 1, um eine Verbindung der Formel (XV) zu liefern

worin R1 definiert ist wie in Anspruch 1, und Reduktion der Verbindung der Formel (XV) und anschließender Reaktion mit einer Verbindung der Formel (III)

worin R4, R5 und n definiert sind wie in Anspruch 1 und LG eine Abgangsgruppe darstellt; e) ein Verfahren, welches die Oxidation einer Verbindung der Formel (II) umfasst, um eine Verbindung der Formel (VII) zu liefern

worin R2 und R3 definiert sind wie in Anspruch 1, gefolgt von der Reaktion der Verbindung der Formel (VII) mit einem Phosphoniumsalz der Formel (XVII)

worin R4, R5, m und n definiert sind wie in Anspruch 1, um eine Verbindung der Formel (XVIII) zu liefern

worin R1, R2, R3, R4, R5, m und n definiert sind wie in Anspruch 1, und Reduktion der Verbindung der Formel (XVIII). 9. Medikament, umfassend wenigstens eine Verbindung der Formel (I) wie definiert in einem der Ansprüche 1 bis 7, oderein pharmazeutisch zulässiges Salz, Enantiomer, Diastereomer oder Solvat davon sowie ein pharmazeutisch zulässiger Arzneistoffträger. 10. Verbindung der Formel (I) wie definiert in einem der Ansprüche 1 bis 7, zur Verwendung als Medikament. 11. Verbindung zur Verwendung nach Anspruch 10, wobei das Medikament zur Behandlung und/oder Prophylaxe einer Sigma-Rezeptor-vermittelten Erkrankung oder eines Zustands dient, wobei die Erkrankung oder der Zustand umfasst: Diarrhö; Lipoprotein-Störungen; Migräne; Adipositas; erhöhte Triglycerid-Spiegel; Chylomikronämie; Dysbe-talipoproteinämie, Flyperlipoproteinämie; Hyperlipidämie; gemischte Hyperlipidämie; Hypercholesterinämie; Hyper-triglyceridämie; sporadische Hypertriglyceridämie; ererbte Hypertriglyceridämie; Dysbetalipoproteinämie; Arthritis; Hypertonie; Arrhythmie; Magengeschwür; Lern-, Gedächtnis- und Aufmerksamkeitsdefizite; Wahrnehmungsstörungen; neurodegenerative Erkrankungen; demyelinisierende Erkrankungen; Abhängigkeit von Medikamenten und chemischen Substanzen, einschließlich Kokain, Amphetamin, Ethanol und Nicotin; Spätdyskinesie; ischämischer Schlaganfall; Epilepsie; Schlaganfall; Stress; Krebs; psychotische Zustände, insbesondere Depression, Angst oder Schizophrenie, Entzündung und AutoimmunErkrankungen. 12. Verbindung zur Verwendung nach Anspruch 10, wobei das Medikament zur Behandlung und/oder Prophylaxe einer Sigma-Rezeptor-vermittelten Erkrankung oder eines Zustands dient, wobei die Erkrankung oder der Zustand Schmerz umfasst, vorzugsweise neuropathischen Schmerz, Entzündungsschmerz oder andere Schmerzzustände, einhergehend mit Allodynie und/oder Hyperalgesie.

Revendications 1. Composé de formule générale (I) :

dans laquelle R1 représente un groupe hétérocyclyle, substitué ou non substitué, aromatique ou non aromatique, le groupe hétérocyclyle étant un radical de noyau stable de 3 à 15 chaînons qui est constitué d’atomes de carbone et de un à cinq hétéroatomes choisis dans le groupe constitué de l’azote, de l’oxygène et du soufre ; un groupe aryle substitué ou non substitué, le groupe aryle étant un groupe contenant de 1 à 3 noyaux distincts ou fusionnés et de 6 à 18 atomes de noyau de carbone ; ou un groupe cycloalkyle substitué ou non substitué, le groupe cycloalkyle étant un radical stable de 3 à 10 chaînons, monocyclique ou bicyclique, qui est saturé ou partiellement saturé ; R2 et R3 sont indépendamment choisis parmi un atome de H et un groupe alkyle en C1 à C6, substitué ou non substitué, de préférence un groupe méthyle ; la substitution de l’un quelconque des groupes substitués définie pour R1, R2 et R3 étant une substitution au niveau d’une ou plusieurs positions disponibles par un ou plusieurs groupes choisis parmi un atome d’halogène ; un groupe cyano ; un groupe hydroxyle ; un groupe nitro ; un groupe azido ; un groupe acyle ; un groupe carboxamido ; les groupes alkyles comportant de 1 à 12 atomes de carbone ; les groupes alcényles comportant une ou plusieurs liaisons insaturées et de 2 à 12 atomes de carbone ; les groupes alcynyles comportant une ou plusieurs liaisons insaturées et de 2 à 12 atomes de carbone ; les groupes alcoxy comportant une ou plusieurs liaisons oxygène et de 1 à 12 atomes de carbone ; un groupe aryloxy ; les groupes alkylthio comportant une ou plusieurs liaisons thioéther et de 1 à 12 atomes de carbone ; les groupes alkylsulfinyles comportant une ou plusieurs liaisons sulfinyle et de 1 à 12 atomes de carbone ; les groupes alkylsulfonyles comportant une ou plusieurs liaisons sulfonyle et de 1 à 12 atomes de carbone ; les groupes aminoalkyles comportant un ou plusieurs atomes de N et de 1 à 12 atomes de carbone ; un groupe aryle carbocylique comportant 6 atomes de carbone ou plus ; R4 et R5 forment ensemble, avec l’atome d’azote auquel ils sont fixés, un groupe hétérocyclyle non aromatique, substitué ou non substitué, le groupe hétérocyclyle étant un radical de noyau stable à 5 ou 6 chaînons qui est constitué d’atomes de carbone et d’un ou plusieurs hétéroatomes choisis dans le groupe constitué de l’azote, de l’oxygène et du soufre ; la substitution dans le groupe hétérocyclyle substitué que R4 et R5 forment ensemble étant une substitution au niveau d’une ou plusieurs positions disponibles par un ou plusieurs groupes choisis parmi un atome d’halogène ; un groupe cyano ; un groupe hydroxyle ; un groupe nitro ; un groupe azido ; un groupe acyle ; un groupe carboxamido ; les groupes alkyles comportant de 1 à 12 atomes de carbone ; les groupes alcényles comportant une ou plusieurs liaisons insaturées et de 2 à 12 atomes de carbone ; les groupes alcynyles comportant une ou plusieurs liaisons insaturées et de 2 à 12 atomes de carbone ; les groupes alcoxy comportant une ou plusieurs liaisons oxygène et de 1 à 12 atomes de carbone ; les groupes alkylthio comportant une ou plusieurs liaisons thioéther et de 1 à 12 atomes de carbone ; les groupes alkylsulfinyles comportant une ou plusieurs liaisons sulfinyle et de 1 à 12 atomes de carbone ; les groupes alkylsulfonyles comportant une ou plusieurs liaisons sulfonyle et de 1 à 12 atomes de carbone ; les groupes aminoalkyles comportant un ou plusieurs atomes de N et de 1 à 12 atomes de carbone ; X représente un atome d’oxygène ou un groupe CH-R12 dans lequel R12 est choisi parmi H, CH3, SH, OH, NH2, CF3, Cl, F, Br, I et CN ; m est choisi parmi 1 et 2 ; n est choisi parmi 1,2, 3 et 4 ; ou un sel, énantiomère, diastéréoisomère ou solvate pharmaceutiquement acceptable de celui-ci. 2. Composé selon la revendication 1, dans lequel R1 est choisi parmi un groupe cyclopentyle substitué ou non substitué, un groupe cyclohexyle substitué ou non substitué, un groupe phényle substitué ou non substitué, un groupe naphtyle substitué ou non substitué, un groupe thiophène substitué ou non substitué, un groupe benzothiophène substitué ou non substitué, un groupe benzofurane substitué ou non substitué, un groupe pyridine substitué ou non substitué et un groupe quinoline substitué ou non substitué ; dans lequel la substitution de l’un quelconque des groupes substitués définis est telle que définie dans la revendication 1. 3. Composé selon la revendication 2, dans lequel R1 est choisi dans le groupe constitué des groupes : 2-thiényle, 3-thiényle, 2,5-dichloro-3-thiényle, 2,3-dichloro-5-thiényle, 2,3-dichloro-4-thiényle, 2-benzothiényle, 3-benzothiényle, 4-benzothiényle, 5-benzothiényle, 7-benzothiényle, 2-benzofuryle, 5-benzofuryle, 2-pyridyle, 3-pyridyle, 4-pyridyle, 2-quinolyle, 3-quinolyle, 5-quinolyle, 6-quinolyle, 3,4-difluorophényle, 3,4-dichlorophényle, cyclopentyle, cyclohexyle, 7-hydroxy-2-naphtyle, 6-hydroxy-2-naphtyle, 5-hydroxy-2-naphtyle, 6-fluoro-2-naphtyle, 6-méthoxy-2-naphtyle, 6-bromo-2-naphtyle, 6-hydroxyméthyl-2-naphtyle, 6-fluorométhyl-2-naphtyle, 7-hydroxy-1-naphtyle, 6-hydroxy-1-naphtyle, 5-hydroxy-1-naphtyle, 5-fluoro-1-naphtyle, 5-bromo-1 -naphtyle et 1-naphtyle. 4. Composé selon l’une quelconque des revendications précédentes, dans lequel R2 est un groupe méthyle et R3 est un atome de H, ou R2 et R3 sont simultanément un atome de H ou un groupe méthyle. 5. Composé selon l’une quelconque des revendications précédentes, dans lequel R4 et R5 forment ensemble un groupe morpholine-4-yle, un groupe pipéridine, un groupe pyrrolidine ou un groupe pipérazine-4-yle. 6. Composé selon l’une quelconque des revendications précédentes, dans lequel n représente 1 ou 2. 7. Composé selon l’une quelconque des revendications précédentes choisi dans le groupe constitué de: 4-(2-((1 -(3,4-dichlorophényl)-5-méthyl-1 /-/-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(2-((5-méthyl-1-(naphtalén-2-yl)-1 /-/-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(3-(1-(3,4-dichlorophényl)-5-méthyl-1 /-/-pyrazol-3-yl)propyl)morpholine, 4-(3-(5-méthyl-1-(naphtalén-2-yl)-1/-/-pyrazol-3-yl)propyl)morpholine, 4-(2-(2-(1-(3,4-dichlorophényl)-5-méthyl-1 /-/-pyrazol-3-yl)éthoxy)éthyl)morpholine, 4-(2-((1 -cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(3-(1 -cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)propyl)morpholine, 1-(3,4-dichlorophényl)-5-méthyl-3-((2-(pyrrolidin-1-yl)éthoxy)méthyl)-1H-pyrazole, 1-(2-((1 -(3,4-dichlorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipéridine, 1-(4-(2-((1 -(3,4-dichlorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)éthanone, (2S,6R)-4-(2-((1-(3,4-dichlorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)-2,6-diméthylmorpholine, 4-(2-((5-méthyl-1-(quinolin-3-yl)-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(4-(1-(3,4-dichlorophényl)-5-méthyl-1 H-pyrazol-3-yl)butyl)morpholine, 4-(3-(5-méthyl-1-(quinolin-3-yl)-1 H-pyrazol-3-yl)propyl)morpholine, 4-(2-((1 -(3,4-dichlorophényl)-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(2-((1-(3,4-dichlorophényl)-4,5-diméthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(3-(1-(quinolin-3-yl)-1 H-pyrazol-3-yl)propyl)morpholine, 4-(4-(1-(3,4-dichlorophényl)-1 H-pyrazol-3-yl)butyl)morpholine, 4-(4-(5-méthyl-1-(quinolin-3-yl)-1 H-pyrazol-3-yl)butyl)morpholine, 4-(3-((1-cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)propyl)morpholine, 4-(2-((1-cyclopentyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, chlorhydrate de 1-(4-(2-((1-cyclohexyl-5-méthyl-1H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)éthanone, chlorhydrate de (3S,5R)-1-(2-((1-cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)-3,5-diméthylpipérazine, chlorhydrate de 4-(2-(2-(1-cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)éthoxy)éthyl)morpholine, chlorhydrate de 4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, chlorhydrate de 4-(2-((1-cyclohexyl-4,5-diméthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, 1-(4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)éthanone, 1-(4-(3-((1-cyclohexyl-1 H-pyrazol-3-yl)méthoxy)propyl)pipérazin-1-yl)éthanone, 1-(4-(4-((1-cyclohexyl-1 H-pyrazol-3-yl)méthoxy)butyl)pipérazin-1-yl)éthanone, 1-(4-(4-((1-cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)butyl)pipérazin-1-yl)éthanone, 1-(4-(3-((1-cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)propyl)pipérazin-1-yl)éthanone, 1-(4-(2-((1-(3,4-dichlorophényl)-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)éthanone, 1-(4-(3-((1 -(3,4-dichlorophényl)-1 H-pyrazol-3-yl)méthoxy)propyl)pipérazin-1-yl)éthanone, 1-(4-(4-((1-(3,4-dichlorophényl)-iH-pyrazol-3-yl)méthoxy)butyl)pipérazin-1-yl)éthanone, 1-(4-(3-((1-(3,4-dichlorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)propyl)pipérazin-1-yl)éthanone, 1-(4-(3-((1-(3,4-difluorophényl)-1 H-pyrazol-3-yl)méthoxy)propyl)pipérazin-1-yl)éthanone, 1-(4-(3-((1-(3,4-difluorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)propyl)pipérazin-1-yl)éthanone, 1-(4-(2-((1-(3,4-difluorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)éthanone, 1-(4-(2-((1-(3,4-difluorophényl)-1H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)éthanone, 4-(2-((1-(3,4-difluorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(2-((1-(3,4-difluorophényl)-1 H-pyrazol-3-yl)méthoxy)éthyl)morpholine, 4-(3-((1-(3,4-difluorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)propyl)morpholine, 1-(4-(2-((1-cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)propan-1-one, 1-(4-(2-((1-cyclohexyl-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)-2-méthylpropan-1-one, 1-(4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)propan-1-one, 1-(4-(2-((1-cyclohexyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)-2-méthylpropan-1-one, 1-(4-(2-((1-(3,4-dichlorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)propan-1-one, 1-(4-(2-((1-(3,4-dichlorophényl)-5-méthyl-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)-2-méthylpropan-1-one, 1-(4-(2-((1-(3,4-dichlorophényl)-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)propan-1-one, 1-(4-(2-((1-(3,4-dichlorophényl)-1 H-pyrazol-3-yl)méthoxy)éthyl)pipérazin-1-yl)-2-méthylpropan-1-one, ou un sel ou solvate pharmaceutiquement acceptable de celui-ci. 8. Procédé de préparation d’un composé de formule (I) tel que défini dans l’une quelconque des revendications 1 à 7, ou d’un sel, énantiomère, diastéréoisomère ou solvate de celui-ci, qui est choisi parmi l’un des procédés suivants : a) un procédé qui comprend la réaction d’un composé de formule (II)

formule dans laquelle R2 et R3 sont tels que définis dans la revendication 1, avec un composé de formule (III)

form ule dans laquelle R4, R5 et n sont tels que définis dans la revendication 1 et LG représente un groupe partant ; b) un procédé qui comprend l’oxydation d’un composé de formule (II) pour obtenir un composé de formule (VII)

formule dans laquelle R1, R2 et R3 sont tels que définis dans la revendication 1, suivie de la réaction du composé de formule (VII) avec un sel de phosphonium de formule (VIII)

formule dans laquelle R4, R= et n sont tels que définis dans la revendication 1, pour obtenir un composé de formule (IX)

(IX) formule dans laquelle R^ R2, R3, R4, R5 et n sont tels que définis dans la revendication 1, et de la réduction du composé de formule (IX) ; c) un procédé qui comprend l’oxydation d’un composé de formule (II) pourobtenir un composé de formule (VII)

formule dans laquelle R1, R2 et R3 sont tels que définis dans la revendication 1, suivie de la réaction du composé de formule (Vil) avec un sel de phosphonium adéquat et d’une hydrolyse acide subséquente pour obtenir un composé de formule (XI)

formule dans laquelle R1, R2, R3 et m sont tels que définis dans la revendication 1, de la réduction du composé de formule (XI) et de la réaction subséquente avec un composé de formule (III)

form ule dans laquelle R4, R5 et n sont tels que définis dans la revendication 1 et LG représente un groupe partant ; d) un procédé qui comprend la réaction de la 3-acétyl-6-méthyl-pyran-2,4-dione avec du magnésium et la réaction subséquente avec un composé de formule (V) :

formule dans laquelle R1 est tel que défini dans la revendication 1, pour obtenir un composé de formule (XV)

formule dans laquelle R1 est tel que défini dans la revendication 1, et la réduction du composé de formule (XV) et la réaction subséquente avec un composé de formule (III)

form ule dans laquelle R4, R5 et n sont tels que définis dans la revendication 1 et LG représente un groupe partant ; e) un procédé qui comprend l’oxydation d’un composé de formule (II) pour obtenir un composé de formule (VII)

formule dans laquelle R1, R2 et R3 sont tels que définis dans la revendication 1, suivie de la réaction du composé de formule (VII) avec un sel de phosphonium de formule (XVII)

formule dans laquelle R4, R5, m et n sont tels que définis dans la revendication 1, pour obtenir un composé de formule (XVIII)

formule dans laquelle R^ R2, R3, R4, R5, m et n sont tels que définis dans la revendication 1, et de la réduction du composé de formule (XVIII). 9. Médicament comprenant au moins un corn posé de form ule (I) tel que défini dans l’une quelconque des revendications 1 à 7, ou un sel, énantiomère, diastéréoisomère ou solvate pharmaceutiquement acceptable de celui-ci et un excipient pharmaceutiquement acceptable. 10. Composé de formule (I) tel que défini dans l’une quelconque des revendications 1 à 7 pour utilisation en tant que médicament. 11. Composé pour utilisation selon la revendication 10, lequel médicament est destiné au traitement et/ou à la prophylaxie d’une maladie ou d’une affection liée au récepteur sigma, dans lequel la maladie ou l’affection comprend la diarrhée ; les troubles liés aux lipoprotéines ; la migraine ; l’obésité ; les taux élevés de triglycérides ; l’hyperchylomicronémie ; la dysbêtalipoprotéinémie ; l’hyperlipoprotéinémie ; l’hyperlipidémie ; l’hyperlipidémie mixte ; l’hypercholestérolémie ; l’hypertriglycéridémie ; l’hypertriglycéridémie sporadique ; l’hypertriglycéridémie congénitale ; la dysbêtalipoprotéinémie ; l’arthrite ; l’hypertension ; l’arythmie ; l’ulcère ; les déficits d’apprentissage, de mémoire et d’attention ; les troubles cognitifs ; les maladies neurodégénératives ; les maladies démyélinisantes ; l’addiction aux drogues et aux substances chimiques, y compris la cocaïne, l’amphétamine, l’éthanol et la nicotine ; la dyskinésie tardive ; l’AVC ischémique ; l’épilepsie ; l’AVC ; le stress ; le cancer ; les états psychotiques, en particulier la dépression, l’anxiété ou la schizophrénie ; l’inflammation ; et les maladies auto-immunes. 12. Composé pour utilisation selon la revendication 10, dans lequel le médicament est destiné au traitement et/ou à la prophylaxie d’une maladie ou d’une affection liée au récepteur sigma, dans lequel la maladie ou l’affection comprend la douleur, de préférence la douleur neuropathique, la douleur inflammatoire ou autres états douloureux comprenant l’allodynie et/ou l’hyperalgésie.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description • WO 9109594 A [0005] · WO 2004017961 A [0015] • EP 0414289 A1 [0006] · US 6492529 B [0016] • EP 0445974 A2 [0007] · WO 04016592 A [0017] • EP 0431943 A [0008] · WO 2006021462 A [0019] • EP 518805 A [0009] · WO 2007098964 A [0019] • WO 02102387 A [0009] · EP 1829866 A1 [0020] • US 4337263 A [0011] · EP 0529973 A [0070] [0080] [0091] • FR 2301250 [0012] · WO 2007079086 A [0071] [0072] [0081] [0086] • US 20030144309 A [0013] [0087] [0092] [0093] • WO 02092573 A [0014]

Non-patent literature cited in the description • WALKER, J.M. et al. Pharmacological Reviews, · Top. Stereochem., 1994, vol. 21, 1 [0076] 1990, vol. 42, 355 [0002] · I. GOSNEY ; A. G. ROWLEY. Organophosphorous • SNYDER, S.H. ; LARGENT, B.L. J. Neuropsychia- Reagents in Organic Synthesis. Academic Press, try, 1989, vol. 1,7 [0002] 1979 [0077] [0084] • QUIRION, R. et al. Trends Pharmacol. Sei., 1992, · Jörg. Chem., 1984, vol.49,4293-4295[0077] [0084] vol. 13, 85-86 [0003] · GABRIEL TOJO ; MARCOS FERNANDEZ. Oxida- • HANNER, M. et al. Proc. Natl. Acad. Sei., 1996, vol. tion of Alcoholes to Aldehydes and Ketones: A Guide 93, 8072-8077 [0003] to Current Common Practice. 2006 [0078] • BURGER. Medicinal Chemistry and Drug Discovery. · Top. Stereochem, 1994, vol. 21, 1 [0083]

Wiley, 2001 [0049] · GABRIEL TOJO ; MARCOS FERNANDEZ. Oxida- • Design and Applications of Prodrugs. Harwood Aca- tion ofAlcoholes to Aldehydes and Ketones: A Guide demie Publishers, 1985 [0049] to Current Common Practice. Springer, 2006 [0085] • KROGSGAARD-LARSEN et al. Textbook of Drug · Tetrahedron Letters, 2010, vol. 51,2741 [0095] design and Discovery. Taylor &amp; Francis, April 2002 · DEHAVEN-HUDKINS, D. L. ; L.C. FLEISSNER ; F.

[0049] Y. FORD-RICE. Characterization of the binding of • J. Am. Chem. Soc., 1998, vol. 120, 6621 [0073] [3H](+)pentazocine to σ recognition sites in guinea [0088] [0094] pig brain. Eur. J. Pharmacol., 1992, vol. 227, 371-378 • Angew. Chem., Int. Ed., 1998, vol. 37, 2090 [0073] [0167] [0088] [0094] · LOWRY, O.H. ; N.J. ROSEBROUGH ; A.L. FARR ; • PAUL N. RYLANDER. Hydrogenation Methods. Ac- R.J. RANDALL. Protein measurement with the Folin ademic Press, 1990 [0075] phenol reagent. J. Biol. Chem, 1951, vol. 193, 265 • Chem. Rev., 1989, vol. 89, 863-927 [0076] [0083] [0168]

Claims (3)

1. HUA?.« n. \ ΙΛΆ'ϋΐ.ϊ.ΎΪ.Κ $i£MA RECEPTOR ΙΝΉΜΓΙΧ>1ΜΜ0^ΐ:: sîiïssi Igén y go PioR h P) ákasáiKs; ki;:««;« vegyek;.

   SS*· m ahol Es jglPPtis«: yKsbSxpíiP|t y|g|:· gziksrbniékPsa.. «uav-ás vag} ppmpikpkgs háktöéiid&amp;s. «hot g lssts?n>akls;s stabil 3P 2 kgP gylpik ssopeit, yotoly sikskioiPbkiP ps egy-bp g kSyoikksok állottá csopottbot vâlisMiit W&amp;Î&amp;AWfà&amp;ï ikUl· rs«z gitrisgig, ox.ggk isfeép; sziibszsgöátt vogy sg;5p?gpí«át&amp;páfi grll shot az ári! 1-3 kíiloeélié vagy ki>e<:e»z:«;t gyúrót Is PP3 gÿüsgseéo-sieínps: iättaiinsgb yyoibbt; vagy Mksziîtpâlt «agy Izpbsgtggäfstlap áikkalldl, ápol a aiktbalkíl síptól PPÖPags Ssoooclklxssos vagy· Ssjciklusns esopop. amvly UífMU vagy sászben telévé; l'E és Es jáksbésá egysskbtói legyeik·!;;; H ás szÂztitpâft vagy sokszbieákstian €:..;; aikík-sopon késül válasz-íptk előnyössé skill; atokay Ek PJ és:MJ osoyorsyupfiftkli tó agy Vagy Mk iciKk'Rszásrt: kló éciyzstbco agy vagy sóbb, a ktovikezők kezűi válasza.;;; csopontal eanáM szábsz:őőien>! jelen;: kaláoPnatote. vlaneeseps;··;; in;Px;\ik;s>fx;;'g nitst-estuxnt: szelő; sviksnpvn: kaiboxatakln csópáit; .1 -13 száoeteíeos aikiksógOíó vgy vagy több tgiitstlén kétéP ás 2- ; 3 s3:á:iialftgkt:krkky3:K0 äikvollcsopoeäok. ágy kggy tipk tél itáStéP RétéE ág g*:1 % PtktPÍIásO|éxto|:; ágy vágy ibitb ostyák kötést is 2;-Ί2 '·§*#^ϊ0ί|ί4>ϊ' sblöxí tpsgbriy agy vagy kibe Métát kötést is M 2 sgiklkkkt'iäkfsitsi«^ä;6 liXöy ykpÿiîÿksïÿi sgy vagy kibb szol:a;il kötési és M2 Mocko-no; pioaln-azé «ItPlsZiptePi ásoponsky agy vagy -óbb szállón; I kokst is M2 sgisMpgiát íiríPlP|«ZP alkilszsé.lboi; csapor-ok: agy vagy ipkb siiitôgéôstoisôl ás M 3 szÄIOipöt taiépitoazé agtkoalM epïppttok; 6 vagy több szénaűnaot taneéoazé: kasbeeiklasos erllc-opeit: E* ás E^ azzsst a títiít>|és;ákíKB:is! egyén, ismgfi.sæiùlï.sSK^1r£ï^.îî"^iôgÿ· «őrssé:; hetesaxekiosi alkotna!·:. ahol a «etgnx.ikU;s sisail 5-vag) P-tay.e avinés esoporl. aeselye; szá;;ei;xnok ás ν:;;>· vegy több. a kövalkozék aiköPa ssppoilbdt választott háivroasoasok alköppgky eéKígán. oxigén, ás kép; ahoi as IG ás IIs ;ikxa agyast aikogax sxais>xöäa;at IxZarosiklax ssidts-okudOja agy v;sgy Rlbh rsrsiaikiixásra állá Oásygálóok ágy vagy 0¾¾ g kOyGkyzOR küldi vlkksMeag ásópíkltiál iOilgOO· MkígiMytóm : csanocsopsn: ikdnxdlesispan; rdhxr-s:x<xxïn; axislo: sdksopo·:?; ko/koxamixfo sáppOtt; s * i 2 ykágkiámöt osrtalaxaax; áikkalógotlülk äv vagy ;Okb takudax; kösáss ás 2 · 12 gzpOaissOsöpiafisiiPkKö kigáíkkypktsrlöky spy vágy idOiStoilíodóp kdáss as 2-12 saáesoxsíá GoxkxoxsO liligiipsOksOiofci agy vagy -old; oxigén kosos; ás 2· ;2 sZáOálömöí gírlgiskkká Mkoxksoponok; agy vagy dóihfeíipálp kötési ás I -dk spéoassoaeî taftälosgöS idkiltkiovopixtok; agy vagy íókk szoikoíl kIMást ás 1-12 ssánátompl inktakoa# dkllsgatiml! oáí-gottük; agy vagy tOOk szoifOaíl késásl ás I -12 sMovRsifesi tíSíS&amp;kssaaé aikidsgtkfek vsopodískx agy vagy íískb íkimgeoaioasot ás 1 s 1.2 szdostöstoí fealMotozd osíksöalkikcsöpoííöki X jaianiása ovigáoatoín vagy CH-R" axgxsg ahoi Rí? ialaaíáse H. Clip Sík OH, Máig CF.;. C!: F. Br. L ás GM küzdi vdlsazogt: »s áriáké 1 ás 3 közöl váJasziod:; 0 ágék* 1« :2,-..¾ Is 4,késői xàlsazioEt; V^IG IGkgyásastilág olfepdkatö síig oovokösievo, dioszí«tx;olzöo:sora vagy sssÍvliP' &amp;< A* i'» i0íwpmismnsni vsgydlop zhoi E'ljMooMse szulsssilgMk vágy szkksikiüaidtláo álkippáiik szoészíkuált vagy szoksztkoálodísis dkkikaxlk saxMazdiylk: vagy spbspitoáiásIáO: losalk SMIöskdMílÖ: vagy szdbszikoáisösn rukkl szaisxsdlxáli vagy szssbsMlloálolfeo öplífg saoksákáolk vagy ssixbxsOíuaiaUan benső-Plán, szOisszOiáik vagy: ssöbsaíitPlalIaO: kasvaoíitrán,; szgpplysli vagy szOkasüiökiallaO gglskg ás sgóbsslgp" lit vagy sááászíkolkdaá kiüxdks közül választan; okol bámiély ínogMoálozötf ssööszlitoált sspoítszübsstili'· ciép m I , igáoypoathao otogitdoii 3. A 3. iglsypoat szsrirtii vegyöl«iS: ahoi R· jáiáütisá aköypikáSÖk slÍOXiS:OságoaÓáiiÍ viksaggg 3>lMoi|,: l-dsak, 2.5-dsMár-3--benib 23-áikiár-5-oanih 2J-dskkd~l'0asdl 2-baasi>baoö. 3-baozooe»íi, 43>y«zMssüIk >· •basxxrbasHl, 7-basisobesbi. i'-bénZdíMI, ô-bansokirib 2-pindik 3-pirklk. -4-parid;;, 2-kx;okl. 3-kkK>ki. á-kx-oiö. O-k.hs'áá, iFa-dOiuoridd, 3 G-d;k lóríadl, áiklOgáptÓ, dkiohexik 7'hKÍr0xl-.s--;xdbg á-bxixoxl-s-nskn, M dddrOgldrindill!, d-fÜJárM-öáiMk MíöáülsiMgpllík ádxóovGoxd-ii, é-l:xixr>xbn;d.ii-á-;xdbk 6-:ösnsxne;b--2--gaili!,. XhkPoxM-aoStik Idi-xJuoJdoxdbk Mhldfoxi-t -naök. 5-iksor- 3 -naíül. 5-br;xn- F-naid; ás ; -ssrikh 4; Álálázd igáilypoxilOk Far-rhîiyikv íísvííbó vcgyükg ahol F/: jviaspása -rahij ás R ' jaivaMsa H. ydgyM" ás R ' jalaravsa ayyi;kiOk:a H vagy sas-ii álgsd igágypápÁ Mnnolylká aládüd x^pülák ilkdl ^ ás R^ ágyüti issöMölifi-ádi 010011410 ásdpösiöt,: pliTOlMki ysopggoi vagy pipaisxxxi-á·;; csoppoí áMpk 0 Mg aiozo igényxxiaíak iiáxxivlyika axvnmi yaayülc·. ahai a á-xáka ! vagy 2^ 7 As aiöaö igéaypo-nok PárraGy ika vágyiiláp asnaiy a kssva;kasok .dkoUa ákOpáilBO 1 xxdaszîonx -1-5::··(( ; -C3,4-dlklÓXlgg|l)->S'-ip<5il- )//-paxïsoi-3-axaekaGMil!)oxo:ddikg d-idMCSímGU-igíMGsMípS-iiy i ;i vy 1 >53 iästiyg; í )sí il 1 IsKsgidial 15¾
2. 4-P dd3:M-dik iólMö3MS-Ü#tií'I MdikáSii iIIprs>plI)morMá:üx.

   4-Ιο4S -moil i-1 g aak&amp;iao-G · Π g-ii/à'pirasx;i-2-i! ρχ<.·ρil;5nariykis. -4-(34 2-5 1 - (3 ;4 >· ; //'·ρί.ΐΧ:<?.ο?-3 - is ?-ei->s s)'-?«? >v;5c?î huiäs. 4 -(2-((1IH -pi s'as??'·! 41) aa4:oki)ff(i 0tm>dïs H·;, 44 3-(5 <4îc>ka\sS-3-mc;ll· ! H'pi3^li^ss^ïpíl-kíss^í'felí??ÿ J --C^i'4iikli>s?res?il>-S-3TSçï(9'-i<2'(pîί'5'όIsç|5n -1-ii)mcK^i>5ïï«iï 1 >--1 ^-4 |Sí54í:ís>^5 Í '{(i ' 4 ( I ' ( :3 s 4-il ïl-itif r pöííil :(-5-¾¾ stíl -1 H-|;513ίΐχ ä?> I -4? - ( I > sï^^îôâ ï Kf î il >p|pör í ííis>TÍ 1-4-(2--4 444'l'4skkn1i?n44S--n-::4i;- !Π-ρ!^;«^3·5!)^<·5:>ϊ4ίί4!!|>ίρ0ί;ϊ.?:!ί;·4 ·;1}:5ί:::ί!'«4ί·. (3S.6R}-4-'(;4{(i .:44-4(kH3í%4D-S'5nő4kH4--p:íí5«ik3-44f?öiov|;::t!;)-2:6-<nní»>1l;nüf(->i;a 4 -{3''u4'^í<?t4- ;--(kim4in-44-4)-ä !Í4>4ssc4-:--4 ·η;·Μ<ΐχί}$:4;4:ΚίΓ(«5ΐη, !-( ::-( i-4 >/k<j;kK:r!en4}'S'-!;^i5l-1 rs-·psf<:i·:-3-í!>?>^sty >«ηorív>i·îϊ. 4-12-(( 142,4-d iklPrícosh-ΙΗ-ρ 4áMI4i - Í0ni4(oxi)4íii}?4<4 jölsk, 4 -(2 4( ( 42.4-4 IkiPríaeS} -4;2-iH 4(4(1! · ! ( í-p:r::s/->k34 k’sKir-bí in. 4 - {2 4) --(ki Ppl iö-3 41)- I Β*ρ4824ΐ -2·“4)(455ρ4)5ΒόΗ4!ϊ&amp; 4-(4 4) --(4,4 ·>2(Μ!ότ))4ύ)'42ΐ“|4ΐ44ίΐί^-24¾)¾¾ (il)Eßör(dli% 4 -(4-(í-mcíli-1 -{Ι·4ηοϋϊ·-34lpH -pifsadl-·® - dliHpilpíKalPlb, 4^^3-=--¾¾ I ^ç.ik.i^h©^âl>-S-KîiÉ>è?î|-^.i 4-(2-((( -ciklopknP î->-m«Pi- ( ( l-piraas!-2 - s s .irr- e io x j W ï i ( ï ?ï ï->r ίο I i n :. 1 --(4424(1 ->2(ki&amp;k&amp;sl42--!M(î|- i (2-íí5s 5í>:>I 2-i( ?:r:v:·c-xi>c;4l>pi|::c-:ra:^i:i:-1 -44^411:¾-n-hïdrakkffid. ( 3 S),. 5 H 2 -1 -( 244((: 5 -1' s K ? « HI k- (S -ίΐιΐίί i ( * 1 ) l - *- i (>îÎ)el4ï4:Î >4 il l>- (2 s ïî-îIs 545 «;ΐ I î(5 (psï'îïà: -- (:- sjtrMâ^ 1 ^ö3kiohfex.i)^5^m^f: ï. Η·^1ϊ^<>1*34.ΐ x0stií 'ö|íö<Hí^o>tlof 442-((( -cik(->he>· (S-i H-|4r;s?ii.4-2-k;;tt^(i^i}eí(5}ríK:íK4iP'(n<.k<4:k>H4: -(42-(( l-cikkdK^ 4-4,5-44^(4--114 - ρ h'<í -îx^ s - 2 - ï Í j==; « îsi: >: J ><4 i ; >33' vï rf o Ih : - h j di- í> k. (o r i d : ! 44-(2-(( : -ciklobasii-) H -pinixo.i-3 -Il 3m<:S->x4d:l)pipcnx4a.·1 -1 IkPaix-n. ;:-çik4iilx;N(l-1Pk-pira2<.4-3-3î.!nK4^xi}prttp2)ps>>£n>7ia· Ρ·4Χ:κ^κ:·χ>. I -44.4(4 } .> g ( κ i) -1 11 -'|> ΐ 5ΐΐ2;<:4 >4| )3¾¾ o4i ï21>ï4S4 ()j>(|ïîî 54¾¾ î ïï - ) -> 5 I^îî^îîîîîïs ? 1 -44-(44(:I csklohoxsi-5-4lsülΊH-psraxok!-ibr-.etokukuk1-piperakip-i4|)skfâm, s 14-(3=4 s-cskioh-ix il44-.;nc?k- i H · ρ I rs aol- 3 - s I }m at ak i ípropi I ; pi para? ί η -141 kakaóik :--(4-(2-((4( 34-4(k.k>r(aali)-i ((·ρ!ί^.Χί;Ρ3-·4)Β«·Χ'Χ!4(;4ρΐρνί<!ΧΙη· I ·ΙΙ4ϊ?«κ>η 1 -(4-(3 4( I -(3,4-4ikiörie;4])-! IkpkaasP· 3-íi}a«:asl(|>ri;p;J)pipi:raxií:- Iklkaraioa. 1 -44-(4-:(( 14 >.4>4ikk>r(en2j-1 |3)p.teö:k?4))^^ 5 --(4 -(3-(( 1 -( ).4-2(kk>r4:4(í-2-sna4l-4 Η -ρΙΐΊ^ί) j--i;kaeîos.l}p:V;|'4!)i;ipt-raxk5· i - ihäkai-ii« 4 44HP40 43,4-4ifks0(:i4p 11)-1 ;Ι- -3 --1 «Ρ ^ T <-C4--((2 - ( ( ( - í (5 > 4-(( ( (11:1(41:1¾ îï i - riísiví:! - ) ( ^ --(ji rö>:4 f! - 2 -41 íkiiök (sk: î ) |>x <)p i i)p ípöí f3 -' 4 ^ î I) síîî kkïs t, 4444:24() >-^íS -dpnam;«.. 144-(:24(i-(2té-dlf kisxskmU-ISi-pini/ol-à-31 )s(«spxl)«(ll)pspera/in- s -Í|)pmpöp, 44:14( 14 à ,4 -piftgoxtkrd 13-3· asaid· 1 H-psnaoS-a - i;)a iotox ; ;cp ÍJiMíM pp 4424(:143,4~44S;Ksríaí!h-1 H-piraaol·-)-3i)(4f(pxl4(1 iknxaioHas 442-4( 1 -(3.,4-41 llpciilkâïlj)-- 2-:(44(( 1-4 l|>pf(&amp;ïi>i-4 - 3)(palpx (ppxlpilïispilpiip, i 44-:(3-(( 1 -::-4: loin; x |(-S-inapi-1.(P-pimao (-3-:2}ρ34χΐχί)ίί3ΐί)ρίρρρχίρ-1 -3)p>'pp;4î-3 -öli {-(-5-(2-(( i-sakk'íkcxiS-á-incP·-1J4-(414¾K€í 1-4-())îyskiXïXidé)?4)p((?«3:ΐϊ4:3(¾-k--ií42--áxptllpmpl4!-í--04í : 44---4-(( I <ikk>hexib I H--|>ira:-XiK).-ílkaétökiRiií)t4pér&amp;xíti·· 1 -4)p«:|xav I.-οα, ! -(4--(2-(( ί -elk IVhexl B 1 fl-pfeXöM VIRbeRxlMsRp ÍRét ékíts-' 1 -4)-2-:4¾¾ Slips Vpag-'I -¼. I -44-(4-(( i ·{.·'. ^jJjkSóHékir-S-HsebRl Η··ρ:ΓΐΐΧ::·43· S1>í-!cK;n:)-:4ilï-ipcrasii!· ? - íh|>;'5XHí.í:··! -or... I -)4-(2-((X:-O514-S-ϊΐϊ«ίil-iM-rsïs:o}--3-;-y;)mssïçixi)ii£li)píp<íísí^ííí-' i'41)-:-2'spçôlp44?asï·- ; -on. ! 44-(2-((4 •{Rs-yikSpriespi)· 4H -p4'i-xc4-3--il)ín<-iuxS)e4hp;pííu;4;'·-·! ·; }pRpx:!!-4--o·; : 44-(2-(( I -{Sj-Xdk'ÁrjíBÜ;--k-i-pköx«}-3--iI«:!<:K>xs)í4j!}pií>«í:X!/· -S ·ί;;--2'Χί5^:1Ιρ;ορ^α··Ι -yp, vagy gv4g>-«íí®sillsg:eiSygssékéió sóié vsgry aMÍ válla. Blj#ás ág 1-4. ígPsypöslok bélyíelyiM skéllsliígsgb^ (1) kégSétii wg\ 01¾¾ vagy sasa. vs'ssexsy-rye?e, dsaasieseesaamcí'e vagy svai viaja vKaiíRásíba. amely a kg vetke xbk egyike kpsbl váisSMtoit: a) eijá-sss. sexek- maglBp :kkB||S: (11) képlees vegyi-lei s-eagákaíéséi

   ähöifvs, R> éy ii5gs1§4í44s as: i;,.^«^ÿ'pKiïsibsïÎ.^sê^à^'ôiÎÎ:, egy síi;) képiek; vggytílgtsyl

   gfeol Rj, Rá éRp jölpslIgsé g.4 I. sgéeypOísiiev; saegsek-ü. és ki.) jeiesPeae sávért-e\op<>ss:. éj eliás-áR töglsilié 4 (Rí i^f>i#|:ô4Vëg^%4'--ô?È.ï«ÎS»ïïÿîât,-is^i>:«»ic= aoî'iïï (¾¾ képiéig Ysgÿôieîéi kspí-pR

   sápi Rg ÍR és % jsteillse sas 1. -gsieyp-e-shaa saegsak-b. ess kweîoea a (Vili képien; vegyijük ívagabaVsé; (VI11) képísü; Kísefö;4y:;i savaI.

   svuk 1¾.¾. R< és« jeiéííásé ak í, (|éüypMSbsS äSsgyäpR mely Pék söms s;X| képle-ií vegyykPei kaparni:,

   (IX) abei Rs. R;. R:;. R:. R< és P(élesítése a:;·· 1. ig:tnype!4bcie mopd«'»:*. vaässaeg s (ÍR) kép lété veayüiel íesiukdéiV. ·:;· eljárás. iSSSieiy magéba;! legi síik is (II) kégléia vegyese; oméácisí-éí . melynek serég .VIR xépleüi vegy élete; kapsak.

   akut Ιχ< Rj Is % \> %^postfeaa:..msg«áöi%· majd «Kt:li8V«ü:#«h-.C'Vil:} kipkiö yggylk!. :teaksí!ö|ái änagklda tXsdoukm-sàvak Is a:n klvaiska savas JndrpiMsg ainlv spap (X!) Rigid« vsgyui<s<s kapu-sb

   ahc-< R,.. K;, R. |:·. ns jcisiiilsc s/ I. iglnygyrsîban vicgadttU. (ΧΊ) képiéig VggyalliR mk&amp;cséià·. es v/1 kèvsïgsn Os) kapissu vegyiPsnd tlcílaó iïsgaUaïsss;

   sh«i R.u R< ss ;R |#leaXsa aK l.Jgênvp0gîpap saigsXaip as líCkjdggbsl tiyöXkesPpRR d) Ipság smalv msgsbaa jpglap kaKsdilR>«Kgil'pm«s-2;4«ik;n WSgáitmsát magglsîgsnMk à»; RdSdPsg s V .> kcgkso Vlgybllt rssgiksaásái

   ahol R< jelentése &amp;s: J /jpivfpeskaRsaívgaíbX. és így ξΧΥ) .kipkíl vsgyüistebkapask

   ah«S R; jábmgsXM L ígSípppspPag nsssal-ys. is a {XV) síp!«;« vagsukd redukcióin;. gR kPvabcu rsagáMtp sál (fb alglcls vegyuVuci

   ahas íg: R; jckstésv Is « Irtiké as 1, Igpp^ppaÉas asigaPiSg Is PP; idiuUlac íáv«.«s urupan· ef sí| áráig aiisíy magábsu fogklja |ÍI) ypiala vagvlkí obdásbifátyigy (Víi) klpMií vegyülök? kapuik

   ahsà R;, R? és R> jekmsse as R igénypontban roegydetk inaid (VU) klplsíü vegyidet reagálksásái fXVi)} klnRn Rí Rmföskíassásssl

   »h-k R .j. R s gîkrukssg sis m és ss 6skk<· ;·? I sgvssyposxhssn s's-sgaskak syy s X VAR kvpíagj vsgyüísRp ksgsAísk

   slsöl Rj, kU R:. R.<, Í-R k-k-ouï:*; Is m sis n RAkké sa R ígéííypkskíkáA e^c<<äoH. valamiig sí RRVll!) kspAm vs-gyakat mRaksAéilR p, Gyógysíss'. asavh &amp;s h -?. IgéRygiRmiR kssraskyike sassim mégMiásyíSsAk AgVkhk köp: sT> kspAA ve-gyíkkíkl IgmRgiigK. vagy gyógylsssílisss sjlRjgaáhaíö séjÉR sRáíRímmsiVR siiMktèsppsïfeili vagy syglyágáí sasi;·;· massa A. öy^yyássSiSísksg srkkgadhssíss ssARRágysIgpi ísAlssfesRk, ÍR. As i ··/. ssAssyjXiSKsR íamnelykv ms-sisn RtóghasásRapR (I) képlxap yssgyplsA gyRgyssmMkí iRRsInsí sl-kmmsíkáRi'íí 1L Ä .! R. Iglspams sswmíi vggyíítekgyslgysgsslslsí íRríkaR slkaiamasissSA shot: a |ÿèg:yss«r«gy·· SidiP«»·* srassapms: álmi kstekíRsít Rsmgség vsígy ilagsif: kiS/xdi-v-Xs kyvagy magklSagssim ssklgáR ahol a Rsispslg vagy á!!;íg*>! a |íRv$?M/4fe'líáí«ítlysklt:fögí*|s::{8^éb8íí:-:has5«ííés:; 'Ujpopmfek-rsni^teissségefe; migiéíg dhMsy «s»#«ÉI íísglkípMsgípty ßliHömferöimsmfa:· à>Âça%ôprôi«ma«m^ %ps?r!ip&amp;pto£dRasmip lypadlpklsíx asssg vsgvsS: isypesilpMssamki; Ripsrk<ílösktersM&amp;;:ssssg hsi^ríHgíksHRsgióig;. syRmáaymí líSpkRAglIsípföskmm; sli'RR-sAs kspmlyigMsmádssm&amp;lsg Rysbsf&amp;lspöpímaiasssmdaí iaRkíi -gVuMâdàsg sksigas vslniyöäRäs; rRgUïSisRvssy íkksIRg tsmkási ·μψμ·, amssMs.*· is Í!gvslsm>R!áayi ksagsdfy madailaassaslpk; ssmsnxlsg&amp;simsíív RsiSipégeR; feöísgskgkk; árogiét és vagy! asysígsskíRk hsAsíém'« sí kakaAsg sía íímiékimmg m agamll ρ sí sdkiiíssP, való ÍRggRskg: sciasdáSs mssssgssyyavswak. ksR-sesssks sssyA«: apPspsAa: sirakv; simssv; rlkygskikkRíR käs állíípöíssk, kdlössRssm a : depmsavul a sasStmígás vagy yk;sv> Míikg gyuksmh: és smmlmmprí Réíégségék,
3. 13,- A H). igémrpvasi ssefÍMi vsygydlíR gyégysssííkésíklSsIkssö ídkaksavsasm, aköl svgyságysps' egy sasgspy spaptm álad kAsveiPsa bsísgsslg vagy slksgöí ksaelsjsám éslvagy msgylRaésRra szolgák ak a! a fessîggsêg vagy ákispsíí smmabasí IRgk! fájdalmak elRnyPsssi aisayöpáiás :fá|dsfeia% gyvakdásos fájdalmat vagy más. ö]!s> dimslvs! éslviîgy lApamlgámsívssUsskA RpmsmaRapsAsR;.